Multiple system atrophy (MSA) …

Robert Fekete MD

Movement Disorders

Updated 05.22.2024
Released 10.04.1993
Expires For CME 05.22.2027

Multiple system atrophy

Author: Robert Fekete MD

See Contributor Disclosures

Multiple system atrophy

In This Article

Quick Link

Introduction

Overview

Multiple system atrophy is a mostly sporadic degenerative disorder with a highly variable anatomic distribution and clinical picture. It typically features some combination of motor parkinsonism, ataxia, and dysautonomia, along with many other less constant signs. Average age at onset is 53 years, and average survival is only 8 years. Although there is no specific treatment, clinicians can palliate many aspects of the syndrome, particularly the dysautonomia and sleep disturbances. The defining pathologic feature is aggregates of alpha-synuclein in oligodendroglia. In this article, the author describes the essential features of multiple system atrophy, including advances in distinguishing it from the other parkinsonian disorders and in managing its many disabling clinical features.

Key points

	• The hallmark of multiple system atrophy pathology is the presence of glial cytoplasmic inclusions.
	• “Red flags” for multiple system atrophy include postural instability within 3 years of disease onset and resulting recurrent falls, wheelchair dependency within 10 years of onset, Pisa syndrome, stridor, inspiratory sighs, severe dysphonia, severe dysarthria, severe dysphagia, and emotional incontinence.
	• Signal loss in dorsolateral putamen on T2 MRI sequences with the presence of a hyperintense lateral rim in fluid-attenuated inversion recovery (FLAIR) sequences has a specificity of 0.97 for discriminating between multiple system atrophy and Parkinson disease.
	• The “hot cross bun” sign, a hyperintensity in the pons on T2 MRI images, is not specific for multiple system atrophy.

Historical note and terminology

Like many heterogeneous disorders, multiple system atrophy was described piecemeal over a period of decades and engenders nosologic controversy. The sporadic form of "olivopontocerebellar atrophy," a term often applied to the cerebellar-predominant variety of multiple system atrophy, was first described by Dejerine and Thomas (41). A dysautonomia-predominant type was described much later (206), as was the parkinsonism-predominant variety, striatonigral degeneration (239; 06; 05). No less historic a contribution was the observation that all varieties of multiple system atrophy share a specific glial cytoplasmic inclusion (163) and that these inclusions are principally composed of alpha-synuclein (65; 44).

The current classification scheme based on the first consensus statement on the diagnosis of multiple system atrophy divides the disorder into a parkinsonian type (MSA-P) and a cerebellar type (MSA-C) (69). These terms replaced the striatonigral degeneration, sporadic olivopontocerebellar atrophy, and Shy-Drager syndrome designations. In the second consensus statement in 2008, definite, probable, and possible multiple system atrophy diagnostic criteria were introduced (70).

Clinical manifestations

Presentation and course

Parkinsonism (rigidity, bradykinesia, and postural instability) occurs in at least 90% of all three types of multiple system atrophy (250). Unlike Parkinson disease, however, multiple system atrophy rarely receives sustained benefit from levodopa and exhibits rest tremor in fewer than 10% of cases (compared with 60% to 70% in Parkinson disease). The progression of parkinsonian motor features of multiple system atrophy, as measured by the motor score (Part III) of the Unified Parkinson’s Disability Rating Scale, averages 28% per year, whereas untreated early Parkinson disease progresses less than 4% per year (200).

Stuttering speech in multiple system atrophy

This patient demonstrates "festinating" speech (rapid stuttering). (Contributed by Dr. Joseph Jankovic.)

Autonomic insufficiency is a more prominent part of most cases of multiple system atrophy than of Parkinson disease and has a marked impact on quality of life (30). Cerebellar features are early and important in many patients and predominate in some. Parkinsonism predominates in others. Because there is considerable pathologic and clinical overlap among the three varieties of multiple system atrophy, there is no need for formal criteria differentiating them. A few patients with multiple system atrophy have isolated dysautonomia, cerebellar dysfunction, or parkinsonism (250).

Besides the classic motor signs, multiple system atrophy is associated with a variety of oculomotor abnormalities, including sustained gaze-evoked nystagmus, square wave jerks, slow and hypometric saccades, diminished vestibular-ocular reflex suppression, internuclear ophthalmoparesis, and reduced vertical gaze (53). Rapid eye movement sleep behavior disorder (RBD) occurs in 69% of patients by history and in 90% of patients by polysomnography (172). The condition occurs earlier and more intensely than in Parkinson disease (90), and its violent, even aggressive motor outbursts can injure the patient or bed partner. Using video-polysomnography, RBD was observed in 43 of 49 (88%) patients with multiple system atrophy; in 81%, bed partners reported some improvement in parkinsonian features during RBD episodes (38). The improvement was also noted by the recordings and included improved movement, speech, and facial expression (50% of patients). A study of 55 patients with multiple system atrophy, found that there was no difference in severity of motor or nonmotor symptoms based on the presence or absence of REM behavior disorder (246).

Even more dangerous is obstructive sleep apnea, which occurs in the later stages and may produce sudden death (140). It may be related either to central alveolar hypoventilation caused by loss of brainstem ventilatory drive centers or to obstructive sleep apnea caused by laryngeal dystonia (243) producing upper airway obstruction (90).

Less frequent or severe features of multiple system atrophy include emotional lability, pyramidal signs, contractures, a tendency to lean laterally while seated (the “Pisa syndrome”), supranuclear ophthalmoplegia, antecollis, an irregular or jerky myoclonic action tremor that is of cortical origin (154), large-amplitude myoclonus, respiratory stridor, polyneuropathy, amyotrophy, distal cyanosis, and Raynaud phenomenon. Young-onset multiple system atrophy (onset before age 40), includes dystonia, dyskinesia, and pyramidal signs and is typically more responsive to levodopa than classic multiple system atrophy (16). Dementia occurs no more commonly than in Parkinson disease (178; 232). There is often a mild normocytic/normochromic anemia that may be caused by loss of sympathetic stimulation of renal erythropoietin production (259).

Most prominent among the dysautonomic findings is orthostatic hypotension, but other important defects are postprandial hypotension, supine hypertension, anhidrosis with thermoregulatory disturbance, poor lacrimation and salivation, constipation, and impotence. Bladder emptying function may also be severely impaired. This usually starts with urgency, but later in the course of many cases, simulates prostatic enlargement in men and stress incontinence in women (17). Bladder dysfunction was found to be the presenting symptom in 18.2% of a cohort of 121 patients with multiple system atrophy (187). In a series of 29 autopsy-confirmed cases evaluated at the Mayo Clinic, rapid progression, early postural instability, poor levodopa responsiveness, and symmetric involvement coupled with progressive adrenergic and sudomotor failure, were highly predictive features of multiple system atrophy (89).

According to Xia and Postuma, normal olfaction, normal cognition, urinary retention, stridor, or respiratory insufficiency are useful for separating multiple system atrophy and Parkinson disease or dementia with Lewy bodies (270). Fanciulli and colleagues propose a 4-point scale for diagnosis of MSA-P with 1 point for each of the following: “postural instability with Hoehn and Yahr stage greater than or equal to 3 within 2 years of disease onset, orthostatic hypotension, overactive bladder symptoms, and urinary retention” (54). A score of 2 or greater is provided as leading to 78% sensitivity and 86% specificity for differentiating between Parkinson disease and MSA-P. A separate study by Fanciulli and colleagues shows 95% specificity for urinary retention for differentiation between MSA-P and Parkinson disease as well as 73% negative predictive value for MSA-P diagnosis in the case of absence of both orthostatic hypotension and urinary disturbance (urinary urgency, incontinence, or retention) (55).

Olfactory function remains preserved in multiple system atrophy as tested via the University of Pennsylvania Smell Identification Test (UPSIT) (75).

Gastrointestinal symptoms, pain, urinary problems, and postural instability due to orthostatic hypotension are reported more frequently in multiple system atrophy than in Parkinson disease, progressive supranuclear palsy, or corticobasal degeneration (31).

Even though multiple system atrophy has been considered to be a disorder without dementia, neuropathologically confirmed cases of multiple system atrophy with cognitive impairment have been reported (12). MSA-P shows a wider involvement of cognitive dysfunction than MSA-C, possibly associated with prefrontal dysfunction (102). Patients with MSA-P have reduced verbal retrieval, whereas patients with MSA-C have difficulties learning new information (14). Frontal lobe-related executive dysfunction and depression were identified in a study of 61 clinically diagnosed probable multiple system atrophy cases (210). Primarily cortical pathology, as well as damage to cerebellar circuits and frontal lobe input from the striatum, are possible contributors to cognitive impairment (217).

The Movement Disorders Society revised the diagnostic criteria in 2022. Clinically established multiple system atrophy is defined as “autonomic dysfunction, poorly levodopa responsive parkinsonism or cerebellar syndrome, two supportive clinical features, and at least one MRI marker.” Clinically probable multiple system atrophy is defined as two of these three features: "autonomic dysfunction, parkinsonism, and cerebellar dysfunction as well as one supportive clinical feature” (255).

Prognosis and complications

As a heterogeneous group, autopsy-proven cases of multiple system atrophy survived a mean of 8.0 years in an autopsy series (86). A meta-analysis of 433 cases gave a mean survival of only 6.2 years (19), with no difference between the parkinsonian type and cerebellar type. This differs somewhat from the findings of a study of 141 patients with moderately severe multiple system atrophy (mean age at symptom onset 56.2± 8.4 years) who had a median survival of 9.8 years (95% CI 8.1-11.4) (251). Shorter survival was suggested by the parkinsonian variant of multiple system atrophy and incomplete bladder emptying, and shorter symptom duration at baseline and absent levodopa response predicted rapid progression. In a large series, median intervals from onset to the need for gait assistance was 3 years, to wheelchair confinement 5 years, to a bedbound state 8 years, and to death 9 years (248). In the final stage, all three variants will produce a rigid, bradykinetic state leading eventually to a bed-bound existence with aphagia and its complications. Rare cases of young-onset multiple system atrophy have been reported with disease duration of 2 to 10 years at last follow-up visit (16; 106).

Levodopa may induce disabling confusion and psychosis and may cause dyskinesias without concomitant motor benefit (86). Sudden death is over seven times as common in patients with dysautonomic predominance than in other forms of multiple system atrophy (224). Another study found that severe generalized autonomic failure and early requirement for bladder catheterization are associated with shorter survival (57). Similarly, in a natural history study 175 patients with probable MSA-P or MSA-C evaluated every 6 months for 5 years with the Unified Multiple System Atrophy Rating Scale (UMSARS) and the Composite Autonomic Symptoms Scale (COMPASS), the median survival from symptom onset was 9.8 years (95% CI 8.8-10.7), but patients with severe symptomatic autonomic failure at diagnosis progressed more rapidly than those without it (129). The presence of MRI changes specific to multiple system atrophy in early disease was correlated with more rapid disease progression in MSA-P (112).

Cases of multiple system atrophy with prolonged survival, which typically start with parkinsonism and development of autonomic dysfunction with a mean latency of 11 years, after which more rapid clinical worsening begins, have been reported by multiple research centers (105; 170; 26). In addition, a case of multiple system atrophy with onset at the age of 34 has been reported (106).

Clinical vignette

A 57-year-old right-handed bookkeeper, on disability, complained of a 6-year history of autonomic symptoms as exemplified by urinary urgency as well as urge incontinence. About 4 years ago, she developed a staggering “drunk” gait, dysarthria, and difficulty with balance. She had multiple falls due to loss of balance. She had no history of lightheadedness. About a year ago, she developed right upper extremity rest tremor as well as REM behavior disorder. She had been taking carbidopa-levodopa, without any response. Her MRI showed cerebellar atrophy.

On physical examination, there was mild saccadic pursuit with saccadic hypometria. Gait was both broad-based and shuffling. There was mild dysmetria on finger-to-nose testing, which was worse on the left side. The patient also had bradykinesia in the bilateral upper extremities, which was worse on the right side, as well as rigidity, which was worse in the right upper extremity. She was diagnosed with probable MSA-C as the cerebellar features were most prominent.

Biological basis

Etiology and pathogenesis

A novel theory of MSA-P being a prion disorder has been advanced by Dr. Stanley Prusiner (176; 260). In his experiments, human embryonic kidney cells infected with basal ganglia samples from deceased patients with a clinical and pathological diagnosis of multiple system atrophy caused neurodegeneration with alpha-synuclein deposition in mice heterozygously expressing mutant human alpha-synuclein (A53T). Toxicity of alpha-synuclein aggregates in a human neuronal cell model is worsened by increased amounts of alpha-synuclein monomer and the presence of aggregates from human Parkinson disease or multiple system atrophy brain homogenates (228). Immunoprecipitation-based real-time quaking-induced conversions are able to distinguish between multiple system atrophy and normal controls (155).

One study has shown an association of multiple system atrophy with various exogenous exposures such as solvents, pesticides, metals, and components of plastics (237). Another showed an association with farming experience (238). There appears to be an inverse association with smoking, as occurs in Parkinson disease, which is independent of the farming association (236; 238). In a population of Korean patients, the risk of multiple system atrophy was independent of participation in agriculture (28). A greater than expected exposure of patients to occupational toxins and frequent occurrence of minor dysautonomic symptoms in their relatives suggest that multiple system atrophy may be caused by a hereditary predisposition to an exogenous chemical toxicant (147).

Genetics. Fewer than 1% of patients have a family history of progressive supranuclear palsy (212). A hint of a specific genetic factor is the unconfirmed association of multiple system atrophy with a specific allele in the genes for interleukin 1-beta (149) and alpha-1-antichymotripsin (64). No mutations have been found in LRRK2, the gene presently considered to be the most commonly mutated in Parkinson disease (225), although LRRK2 was found to colocalize with glial cytoplasmic inclusions in laboratory studies (96). Single nucleotide polymorphisms at the SNCA locus, which codes for alpha-synuclein, have been associated with increased risk for developing multiple system atrophy (194). Scholz and colleagues propose that instead of direct amino acid sequence alteration, differences in expression of the SNCA gene may contribute to the development of multiple system atrophy. The G51D mutation of SNCA was identified in a case of young-onset Parkinson disease with both neuronal and glial cytoplasmic inclusions of alpha-synuclein demonstrating features of both Parkinson disease and multiple system atrophy (104). A53E mutation was also associated with multiple system atrophy (135). F-box only protein 7 (FBXO7) mutations are also a cause of young-onset Parkinson disease (43), and this protein was found to colocalize with alpha-synuclein in Lewy bodies of Parkinson disease and glial cytoplasmic inclusions of multiple system atrophy (274). Mutations in COQ2, the gene encoding coenzyme Q10, were found in six families with multiple family members affected by multiple system atrophy (139). Mutations of this gene, such as the V343A variant, may be susceptibility factors for developing sporadic multiple system atrophy. This variant is now referred to as V393A (c.1178T--> C (p.V393A)) given that the incorrect start codon was initially used for reference (97). This variant was not found in a European cohort of 788 patients with multiple system atrophy (201). A Caucasian patient with severe MSA-C pathological changes was reported to have COQ2 p.S146N heterozygous variant (151). Sequencing of COQ2 in a Chinese cohort of 116 patients with MSA-C revealed changes in this gene in three patients: p.L402F and P.R173H missense and p.A32A synonymous mutation (249). In an Italian study of 87 patients with probable multiple system atrophy, homozygous p.A43G mutation was found in a single patient with MSA-C, but according to further analysis, this variant was not pathogenic (183). Decreased levels of coenzyme Q10 were found in postmortem cerebellar specimens of patients with multiple system atrophy (15). In a study of 40 patients with multiple system atrophy, plasma COQ10 levels correlated with motor symptoms in MSA-C only (47). A genome-wide association study by Sailer and colleagues did not find evidence of association of multiple system atrophy with COQ variants; further research is needed regarding this gene in Asian populations (186; 193). Microglial activating gene TREM2 variant p.R47H is suspected of increasing risk of developing multiple system atrophy (152).

A patient with MSA-C diagnosis due to ataxia and autonomic dysfunction with a family history of amyotrophic lateral sclerosis was found to have C9orf72 repeat expansion (73).

Pathology. The hallmark of multiple system atrophy pathology is the presence of glial cytoplasmic inclusions (234; 269; 96). Glial cytoplasmic inclusions are most consistently present in the external and internal capsules, the central tegmental tract, and the white matter of the cerebellar cortex (10). Alpha-synuclein filaments in multiple system atrophy have a conformation that is different from filaments in diffuse Lewy body disease (198). The glial cytoplasmic inclusion pathology may be caused by internalization of pathological alpha-synuclein into oligodendrocyte precursor cells (98). The mechanism that selects for glial accumulation of alpha-synuclein and preference for the particular alpha-synuclein conformation in glial cytoplasmic inclusions as opposed to the Lewy body conformation has not yet been elucidated (27).

A case with abundant glial cytoplasmic inclusions, but not fulfilling diagnostic criteria for multiple system atrophy, has been reported (164). Of unknown significance is a case of hypoparathyroidism with basal ganglia calcifications in addition to multiple system atrophy pathology and phenotype. Massive lipid-laden macrophage infiltration of the pontocerebellar fibers was described in one case (267).

In a postmortem study of 35 patients with multiple system atrophy, Cykowski and colleagues additionally found neuronal inclusions of alpha-synuclein in the striatum, substantia nigra, anterior cingulate, amygdala, entorhinal cortex, basal forebrain, hypothalamus, and cerebellar roof nuclei (37). Salvesen and colleagues found neuronal loss in frontal and parietal cortex, which may correspond to cognitive impairment in multiple system atrophy (190).

In MSA-P, there is cell type-specific neuronal loss, with calcineurin-positive medium spiny neurons depleted in the posterior putamen as compared to choline acetyltransferase-positive neurons (191). A subsequent study showed that in the caudal and dorsolateral putamen, calbindin-positive neurons are more affected than calcineurin-positive neurons (192). Hyperechogenicity of the lentiform nuclei on transcranial sonography has been found in MSA-P and progressive supranuclear palsy, but it’s unclear what underlies this finding (181).

Lewy body pathology has been found in submandibular glands of patients with Parkinson disease and incidental Lewy body disease, but not in patients with multiple system atrophy (42).

Neuronal cell loss has been reported in the Onufrowicz nucleus and the intermediolateral cell column, as well as a portion of the intermediate reticular formation, dorsal motor nucleus of vagus, nucleus ambiguus, caudal raphe nucleus, arcuate nucleus, pontine micturition center, and locus ceruleus (159). Rostral raphe neurons are relatively preserved in multiple system atrophy, in contrast to diffuse Lewy Body disease (18). The pedunculopontine nucleus has also been implicated in multiple system atrophy (144).

A rare association of multiple system atrophy with Alzheimer disease has been described (184). Alpha-synuclein and phosphorylated tau colocalize in certain brain regions in cases of combined multiple system atrophy and Alzheimer disease (230). Blood-brain barrier dysfunction has been found to correlate with disease severity in multiple system atrophy (214).

Cell biology. Glial cytoplasmic inclusions include hyperphosphorylated alpha-synuclein, ubiquitin, LRRK2, as well as other proteins, including F-box only protein 7 (96; 43; 274). Phosphorylated alpha-synuclein at serine 87 and 129 has been detected in multiple system atrophy brains, but not in controls (161). On the other hand, a series of 58 patients with multiple system atrophy was negative for alpha-synuclein mutations (123). In an animal model of multiple system atrophy, alpha-synuclein knockout mice appeared to be resistant to 3-nitropropionic acid-induced neuronal loss and dendritic pathology (235). In an oligodendroglial cell line, expression of tubulin polymerization promoting protein (TPPP)/p25 triggered formation of alpha-synuclein positive cytoplasmic inclusions and apoptotic cell death (254).

Dysfunction of the ubiquitin-proteasome system has been reported in multiple system atrophy (24). Phosphorylation of DARPP32, a major substrate of cdk5, may be involved in the formation of oligodendrocyte glial cytoplasmic inclusions (84). Reduction in LRRK2 expression in oligodendroglia is associated with increased neuronal loss in multiple system atrophy, but parkin immunoreactivity has been seen in only a small proportion of glial cytoplasmic inclusions (85). An oligodendroglial protein, p25alpha, which interacts with myelin basic protein, migrates to glial cytoplasmic inclusions (215). NUB1, a synphilin-1-interacting protein, is found in the intracytoplasmic inclusions of both neuronal and oligodendroglial cells, neuronal nuclear inclusions, and swollen neurites (227). HtrA2/Omi, a mitochondrial proapoptotic serine protease that is released into the cytosol, has been found in glial and neuronal cytoplasmic inclusions in multiple system atrophy brains (103).

Transcranial magnetic stimulation with triple stimulation technique detects corticospinal tract involvement in multiple system atrophy (52). Median nerve somatosensory evoked potential measurement shows slowing of the central sensory conduction time as the disease progresses (138). Microvessel degeneration has been found in medullary autonomic nuclei (136).

High levels of CSF axonal biomarkers are found in MSA-P. Neurofilament light chain, heavy chain, and tau are significantly increased in MSA-P (all p < 0.0001), whereas noradrenergic metabolite 3-methoxy-4-hydroxyphenylethyleneglycol levels are significantly decreased in MSA-P (p < 0.0001) as compared to Parkinson disease (01). No difference in biomarkers has been found between MSA-C and MSA-P (02). CSF hypocretin (orexin) levels are normal (133). Although neurofilament light chain can differentiate between Parkinson disease and atypical parkinsonism, it cannot differentiate between multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration (33). DJ-1 CSF levels alone or in combination with CSF tau levels can differentiate multiple system atrophy from Parkinson disease (81). A review by the multiple system atrophy biomarkers initiative reveals that DJ-1, alpha-synuclein, total-tau in combination with neurofilament light chain, and catecholamine metabolite levels are the most promising biomarkers so far (118). Singer and colleagues also proposed neurofilament light chain, total alpha-synuclein, and catecholamine metabolite 3,4-dihydroxyphenylacetic acid as possible biomarkers (209). In addition, coenzyme Q10 is being investigated as a peripheral biomarker for multiple system atrophy due to association of the disease with COQ2 mutations as a risk factor for sporadic multiple system atrophy in the Japanese population (114). Measurement of alpha-synuclein in blood exosomes identified by oligodendroglial versus neuronal markers may distinguish multiple system atrophy from Parkinson disease (48).

Pathophysiology. Patients with multiple system atrophy have neurogenic orthostatic hypotension and decreased baroreflex function, with a relatively preserved cardiac sympathetic innervation (88; 223). A relatively high frequency of cardiac ectopy has been found (74). Autonomic dysfunction can be exacerbated by medical treatment of other symptoms (275). Resting baroreflex sensitivity has been shown to be lower in a group of 35 patients with multiple system atrophy (60). Postsynaptic sympathetic nerves in the epicardium are affected in multiple system atrophy (157; 158), but the changes are less prominent than in Parkinson disease or diffuse Lewy Body disease (159). Awake ventilatory response to hypercapnia and hypoxia appears to be affected later in the disease course than baroreflex function (127). In a group of patients with multiple system atrophy who suffered sudden death as compared to patients with multiple system atrophy who died from well-established causes, depletion of serotonergic neurons in the ventrolateral medulla and nucleus raphe obscurus was present (223). Neurons in the intermediolateral cell column, as well as catecholaminergic neurons in the ventrolateral medulla, were affected equally in both groups.

Growth hormone release in response to arginine is impaired in multiple system atrophy, but not in Parkinson disease (159). This response to arginine can also differentiate MSA-P from progressive supranuclear palsy (169). The clonidine stimulation test for growth hormone release has higher sensitivity and specificity for differentiating MSA-P and Parkinson disease. A combination of clonidine and arginine tests could further enhance sensitivity and specificity (273).

In a study, patients with multiple system atrophy were found to have pupillary sympathetic dysfunction from an early stage, whereas in patients with Parkinson disease, it tended to gradually accelerate at a more advanced stage of the disease (266). Pupillography may distinguish multiple system atrophy from Parkinson disease (180). In multiple system atrophy patients, pupillary sympathetic sensitivity has been correlated with the severity of orthostatic hypotension during a head-up tilt test and with the elevation of systolic blood pressure during a noradrenaline infusion test (266).

Blunted heart rate (59) and electroencephalographic changes during period limb movements of sleep have been observed in multiple system atrophy (242). Decreased R-R interval variability and impaired sympathetic skin response correlate more with multiple system atrophy than Parkinson disease (21). Skin sympathetic dysfunction has also been demonstrated via impaired vasodilator response to local heating (265).

Postprandial hypotension correlates with degree of orthostatic hypotension in multiple system atrophy and is ameliorated by acarbose, possibly due to decreased postprandial secretion of glucagon-like peptide 2 (GLP-2) (63).

In an electromyography study, the mean duration of motor unit potentials recorded from the external anal sphincter was significantly longer in patients with multiple system atrophy and progressive supranuclear palsy compared with motor unit potentials recorded from patients with Parkinson disease (P < 0.005 for both) (258).

Chronic orthostatic hypotension in patients with multiple system atrophy leads to structural remodeling of veins and reduced venous compliance, which actually serves to counteract excessive venous pooling in the lower extremities (125).

Epidemiology

At a large referral center, 100 patients with multiple system atrophy reported a median age at onset of 53 years (range 33 to 76 years) (250), whereas another registry reported a mean age at onset of 60 years (SD=9; range 34 to 83 years) (218). In a study of the natural history of multiple system atrophy in the United States by Low and colleagues, median survival from symptom onset was 8.9 years, with presence of severe autonomic failure signaling worse prognosis (median survival of 8 vs. 10.3 years) (129). Degree of autonomic failure, urinary catheterization within 3 years of onset, bladder symptoms within 3 years of onset, older age of onset, and falls within 3 years of onset were found to be associated with worse prognosis in a study by Coon and colleagues (34). In Jellinger's unpublished series of 600 autopsied brains from patients with parkinsonian disorders, multiple system atrophy occurred in 5.1% (178). The sexes appear to be affected equally (218). The incidence in the 50- to 99-year age group has been measured at 3.0 new cases per 100,000 person-years (22), and the prevalence in a medically based series in London was 4.4 per 100,000 population (195), about 3% of that of Parkinson disease. The annual incidence of new cases is about 0.6 per 100,000 population (237; 218). The crude incidence of MSA-P in northern Sweden is 2.1 per 100,000 (124). In Iceland, the incidence was 0.7 per 100,000 and the prevalence was 3.4 per 100,000 (20). Multiple system atrophy of the cerebellar type comprises 29% of the cases of sporadic, adult-onset ataxia (03). Rare cases of multiple system atrophy with onset prior to the age of 40 have been reported (106).

Also see the article on Epidemiology of movement disorders.

Differential diagnosis

Clinical and imaging findings of sporadic adult-onset ataxia of unknown etiology have some overlap with multiple system atrophy (04). Although multiple system atrophy is considered a sporadic disease, four families, one of which had a consanguineous marriage, were reported with familial cases of multiple system atrophy phenotype with autonomic failure, parkinsonism, and cerebellar ataxia (79). These patients were negative for spinocerebellar ataxia types 1, 2, 3, 6, 7, 12, 17, dentatorubral-pallidoluysian atrophy, and alpha-synuclein mutations. A clinical review of 249 sporadic adult-onset degenerative ataxia cases found higher scores on the Scale for the Assessment and Rating of Ataxia (SARA) in cases that met MSA-C criteria compared to those that did not (71).

Spinocerebellar ataxia type 2 may present with a parkinsonian or cerebellar phenotype and should be considered in the differential diagnosis, especially if an autosomal dominant inheritance pattern is established (117; 268). Spinocerebellar ataxia type 3 has also been reported with a multiple system atrophy phenotype (264). Aprataxin mutations leading to ataxia with oculomotor apraxia can also have an overlapping phenotype with MSA-C (13).

Autonomic dysfunction in late-onset cerebellar ataxia complicates differential diagnosis with MSA-C (121). An SCA17 case with progressive ataxia, autonomic dysfunction, parkinsonism, supranuclear gaze palsy, and cognitive impairment has been reported (122). A case of SCA17 with reduced penetrance given 41 CAG repeats (44 repeats are needed for full penetrance) was reported. This patient had lack of putaminal hyperintense rim, but did have urinary incontinence and erectile dysfunction. Although he fulfilled diagnostic criteria for probable multiple system atrophy, the overall clinical picture was more consistent with SCA17 (46). In contrast, a series of 199 patients with a clinical diagnosis of multiple system atrophy was negative for SCA12 (29). In addition, hereditary spastic paraplegias, fragile-X tremor ataxia syndrome, mitochondrial disease, Gaucher disease, Perry syndrome, and cerebrotendinous xanthomatosis can potentially mimic multiple system atrophy (216).

“Red flags” with greater than 95% specificity for MSA-P as opposed to Parkinson disease include postural instability within 3 years of disease onset and resulting recurrent falls, wheelchair dependency within 10 years of onset, Pisa syndrome (prolonged episodes of lateral trunk flexion), disproportionate antecollis (240), contractures of hands or feet excluding Dupuytren disease, diurnal inspiratory stridor, nocturnal inspiratory stridor, inspiratory sighs, severe dysphonia, severe dysarthria, severe dysphagia, and emotional incontinence (110). Laryngeal abductor paralysis (143), generally occurring in advanced stages of multiple system atrophy, has also been reported in the early stages (40). It may lead to nocturnal sudden death (50). Stridor is a high-pitched inspiratory sound associated with laryngeal dysfunction (35). Laryngoscopy and video polysomnography may be useful for diagnostic confirmation of stridor (35). Stridor may have different patterns based on multiple system atrophy phenotype. Todisco and colleagues found that MSA-P has a dystonic pattern, whereas MSA-C had a dystonic pattern with additional neurogenic findings on vocal cord EMG (233).

“Cold hand sign,” with poor circulatory return after blanching, is a clue for multiple system atrophy with poorly understood pathophysiology (171). Lower limb tremor, although a possible presentation of Parkinson disease, may be suspicious for multiple system atrophy (80). Symmetric symptoms, which were reported in 48% of a cohort of patients with MSA-P, should also increase suspicion for this disorder when evaluating patients with Parkinson disease (76). Emotional incontinence exhibited by inappropriate laughter or crying has also been reported in 36% of a series of patients with MSA-C (165). “Cold hand sign” with palmar skin temperature less than 28°C was reported in 6% of multiple system atrophy cases and no Parkinson disease or normal control cases (11).

The presence of excessive square-wave jerks, mild to moderate hypometria of saccades, impaired vestibulo-ocular reflex suppression, spontaneous nystagmus, or positioning downbeat nystagmus may be oculomotor clues to the presence of multiple system atrophy, whereas the presence of clinically slow saccades or moderate to severe gaze restriction argues against multiple system atrophy (08). Of note, hypometric saccades have been reported in Parkinson disease (09). Ocular jaw synkinesia, described in Parkinson disease, is not seen in MSA-P (189).

Differentiation of MSA-P from the subset of patients with Parkinson disease and diffuse Lewy body disease with prominent autonomic failure is a profound diagnostic challenge. In a retrospective study of 134 patients with clinical diagnosis of multiple system atrophy on whom subsequent pathological evaluation was performed, the diagnostic accuracy of multiple system atrophy versus diffuse Lewy body disease, Parkinson disease, and progressive supranuclear palsy was 64%, with autonomic failure in patients with diffuse Lewy body disease and Parkinson disease as the main cause of misdiagnosis of multiple system atrophy (109). In a prospective study of patients with multiple system atrophy and Parkinson disease, scores on self-report questionnaires of autonomic symptoms as well as on clinical assessments of autonomic function were similar in the two groups (126). The pattern of anhidrosis is different in the two groups. Intact quantitative sudomotor axon testing in anhidrotic areas confirmed a preganglionic lesion in multiple system atrophy patients, whereas patients with Parkinson disease had anhidrosis due to a peripheral lesion (126). Postganglionic sudomotor denervation reported in a study confounds this diagnostic method (175).

Alpha-synuclein pathology was seen on colonic biopsy of the enteric nervous system in one out of six patients with multiple system atrophy and in five out of nine patients with Parkinson disease (174). Thus, although synuclein pathology is less common in multiple system atrophy than in Parkinson disease, it may involve the entire enteric nervous system.

Although progressive supranuclear palsy parkinsonism (PSP-P) shares many features with multiple system atrophy, autonomic dysfunction is uncommon in this disorder and can help distinguish it from multiple system atrophy (257). In a study by Koga and colleagues, the prominent cerebellar features of the cerebellar subtype of progressive supranuclear palsy (PSP-C) led to misdiagnosis as MSA-C (109).

Corticobasal degeneration may be confused with multiple system atrophy, but the former is highly asymmetric and always shows important apraxia and cortical sensory loss. The multiple system atrophy with a predominance of dysautonomia may be confused with progressive autonomic failure. However, the dysautonomic features in multiple system atrophy typically start with bladder and erectile dysfunction, proceeding to thermoregulatory difficulty and orthostatic hypotension, and finally to ventilatory dysrhythmias. Progressive autonomic failure, on the other hand, begins with thermoregulatory and blood pressure dysregulation; bladder dysfunction occurs last, and ventilatory arrhythmias do not occur (131).

In a large series of patients carrying a diagnosis of multiple system atrophy of the cerebellar type, 4% (3 of 76 patients) had a mutation in the FMR1 gene, suggesting that fragile-X-associated tremor-ataxia syndrome should be considered in the differential diagnosis (99).

Multi-infarct states may mimic multiple system atrophy and many other degenerative disorders but are usually identified by vascular lesions on MRI scan, arteriosclerotic risk factors, and a history of stepwise progression. Additionally, a rare case of multiple system atrophy masking symptoms of multiple sclerosis has been reported (58). Cases of pure autonomic failure do not have the additional parkinsonian or cerebellar signs of multiple system atrophy on physical examination.

Diagnostic workup

MRI will help rule out a multi-infarct state or normal-pressure hydrocephalus as a cause of dopa-unresponsive parkinsonism and will also rule out an anatomical lesion of the cerebellum.

The “hot cross bun” sign is a hyperintensity in the pons on T2 MRI images of MSA-C (07; 205). Of note, the “hot cross bun” sign has also been observed in spinocerebellar ataxia types 2 and 3, parkinsonism secondary to vasculitis, and variant Creutzfeldt-Jacob disease (25; 141; 23; 211). This sign may be clearer on T2* imaging as compared to T2 (185).

Putaminal atrophy can differentiate multiple system atrophy from Parkinson disease (23; 199). Meta-analysis of six studies confirmed a statistically significant reduction in putamen volume in multiple system atrophy as opposed to Parkinson disease (188). Signal loss in dorsolateral putamen on T2 MRI sequences with the presence of a hyperintense lateral rim in fluid-attenuated inversion recovery (FLAIR) sequences has a specificity of 0.97 for discriminating between multiple system atrophy and Parkinson disease (244). Although specificity is high, sensitivity of these signs on 1.5 Tesla MRI in early stages of the disease is suboptimal (23; 199). Hyperintense putaminal rim on three Tesla T2 images by itself may be a nonspecific finding (23; 199). Presence MRI changes specific for multiple system atrophy were associated with faster clinical progression in a post-hoc analysis of the multiple system atrophy–rasagiline study (112).

“Pointers” raising the possibility of multiple system atrophy also include hyperintensity of the middle cerebellar peduncle, pons, and cerebellum (199). Susceptibility-weighted MRI (78), as well as magnetic resonance spectroscopy (77), may help in differentiating between multiple system atrophy and Parkinson disease. The European Multiple System Atrophy Study Group found that severity of orthostatic hypotension was not associated with multiple system atrophy subtype and that sensitivity to pick up orthostatic hypotension increases from 54% at 3 minutes to 72% with a prolonged 10-minute orthostatic challenge (168).

A set of diagnostic criteria proposed by Quinn (178) was modified and operationalized by a Consensus Conference in 1999. The criteria from the Second Consensus Conference are outlined here (70). The Movement Disorders Society also published 2022 criteria for clinically established multiple system atrophy consisting of dysautonomia plus poorly levodopa responsive parkinsonism or cerebellar syndrome and clinically probable multiple system atrophy with at least two of the following: dysautonomia, parkinsonism, or cerebellar syndrome (72).

A validated disability rating scale is available (256).

Table 1. Multiple System Atrophy Diagnostic Criteria

Definite multiple system atrophy	Requires neuropathologic finding of widespread and abundant central nervous system glial cytoplasmic inclusions that are positive for alpha-synuclein, in association with neurodegeneration in striatonigral or olivopontocerebellar structures.
Probable multiple system atrophy	A sporadic, progressive adult-onset (after the age of 30) disease characterized by autonomic failure involving urinary incontinence plus erectile dysfunction in males, or an orthostatic decrease of blood pressure within 3 minutes of standing by at least 30 mmHg systolic or 15 mmHg diastolic, and
	• poorly levodopa-responsive parkinsonism (bradykinesia with rigidity, tremor, or postural instability)
	or
	• a cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction).
Possible multiple system atrophy	A sporadic, progressive adult-onset (after the age of 30) disease characterized by parkinsonism or a cerebellar syndrome and
	• at least one feature suggesting autonomic dysfunction otherwise unexplained urinary urgency, frequency, or incomplete bladder emptying; erectile dysfunction in males; or significant orthostatic hypotension decline that does not meet the level requirements in probable multiple system atrophy, and
	• at least one additional feature from Table 2.
(70)

Table 2. Additional Diagnostic Criteria for Possible Multiple System Atrophy

Possible MSA-P or MSA-C	• Babinski sign with hyperreflexia • Stridor
Possible MSA-P	• Rapidly progressive parkinsonism • Poor response to levodopa • Postural instability within 3 years of motor onset • Gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction • Dysphagia within 5 years of motor onset • Atrophy on MRI of putamen, middle cerebellar peduncle, pons, or cerebellum • Hypometabolism on FDG-PET in putamen, brainstem, or cerebellum
Possible MSA-C	• Parkinsonism • Atrophy on MRI of putamen, middle cerebellar peduncle, pons, or cerebellum • Hypometabolism on FDG-PET in putamen • Presynaptic nigrostriatal dopaminergic denervation in SPECT or PET
(70)

Investigational diagnostic methods. Numerous studies evaluating possible additional diagnostic methods to separate multiple system atrophy from clinically similar disorders have been performed. Given the rarity of multiple system atrophy, these usually involve small numbers of subjects. Many involve advanced imaging acquisition and analysis methods that may not be readily available in daily clinical practice.

Fractional anisotropy and apparent diffusion coefficient changes are present prior to hyperintense putaminal rim on MRI sign and may be used to differentiate multiple system atrophy from Parkinson disease (93). A scoring system of putaminal atrophy, signal hypointensity, and abnormal disruption of the hyperintense lateral rim of the putamen on 3T MRI had sensitivity of 70.6% and specificity of 93% for distinguishing between Parkinson disease and early MSA-P as shown in a 3-year follow-up study (119). Correlating with putaminal atrophy on imaging studies, on gross specimens, there is dorsal atrophy and darkening of the putamen due to lipofuscin, neuromelanin, and increased iron (95).

Hypometabolism on fluorodeoxyglucose positron emission tomography (FDG-PET) in the brainstem, cerebellum, or putamen, as well as presynaptic nigrostriatal dopaminergic denervation in SPECT or PET, are included in the diagnostic criteria (70). A variety of investigational techniques have potential for the differentiation of multiple system atrophy and Parkinson disease, as well as between the subtypes of multiple system atrophy. In PET testing, putamen to substantia nigra ratios and putamen to caudate ratios of 6-[18F]fluorodopa-derived activity as well as cardiac 6-[18F]fluorodopamine-derived activity separate Parkinson disease from multiple system atrophy (75; 115). Also, 123I-Ioflupane scanning can be used to differentiate multiple system atrophy from Parkinson disease (177). Reduction in AChE activity as measured by [(11)C] N-methylpiperidin-4-yl propionate PET has been seen in the thalamus (-27%) and the posterior lobe of cerebellar cortex (-36%) in patients with MSA-C (82). A fully automated, voxel-based FDG-PET method has been shown to differentiate multiple system atrophy from Parkinson disease and controls (49). Analysis of metabolic patterns visualized via [18F]FDG PET by Kim and colleagues classified multiple system atrophy into three metabolic categories: striatal, cerebellar, and mixed hypometabolism, with striatal and mixed groups showing corresponding striatal dopamine transporter loss on ([18F]FP-CIT) PET imaging (107). Substantia nigra hyperechogenicity on transcranial sonography, seen in Parkinson disease, was observed less frequently in Japanese patients with multiple system atrophy (153). Transcranial sonography could also distinguish between patients with Parkinson disease and atypical parkinsonism in a German population (245). Of note, 10% of the population has been found to have abnormal echogenicity of the substantia nigra (261). Differences in cardiac and whole-body metaiodobenzylguanidine (MIBG) imaging are seen between multiple system atrophy and Parkinson disease (132).

Voxel-based morphometry as well as tractography are not appropriate for the diagnostic workup of individual patients, but they offer important research insights (23). Morphometric measurement of midbrain and pons can distinguish MSA-P and progressive supranuclear palsy (36). Additionally, putamen/caudate volume ratios on MRI scans can also differentiate between multiple system atrophy and Parkinson disease (204). Voxel-based morphometry and relaxometry comparison of MSA-P and MSA-C shows infratentorial differences, namely, stronger reduction of gray matter in the cerebellum and white matter in the brainstem, as well as reduction of the relaxation rate R2 in the cerebellum and brainstem (137). MSA-P does not show any changes in the superior cerebellar peduncle (100). On tractography-based analysis, MSA-C cases display decreased fractional anisotropy and volume as well as increased apparent diffusion coefficient values in the middle cerebellar peduncle, compared to controls (229). Diffusion tensor imaging indexes correlate with severity of orthostatic hypotension and disease duration in MSA-C (231). Location of degenerated pontocerebellar tracts on diffusion tensor imaging corresponds to the transverse portion of the hot cross bun sign (62). MSA-C can be differentiated from Parkinson disease via computer-assisted statistical analysis of brain perfusion SPECT images (247). Song and colleagues found a difference in occipital Tc-99m hexamethylpropyleneamine oxime (HMPAO) perfusion SPECT between MSA-P and mild Parkinson disease (213). Three-dimensional fractal analysis (262) and voxel-based morphometry (145) can also show cerebellar volume loss in MSA-C. Three-dimensional “gyrification index” of the cerebellum based on T1-weighted MRI images can be used to differentiate MSA-C from controls (263). Mean diffusivity values of brainstem and cerebellar hemispheres derived from diffusion-weighted MRI imaging were higher in both subtypes of multiple system atrophy as compared to the Richardson syndrome variant of progressive supranuclear palsy and Parkinson disease (148).

11C-raclopride PET scanning, using both D2 receptor binding potential and cerebral influx ratio, can distinguish patients with MSA-P and Parkinson disease better than current striatal D2 receptor-only analysis (241). There is a higher rate of signal reduction in caudate and anterior putamen in MSA-P as compared to Parkinson disease on [(123)I]β-CIT SPECT (150).

There is a 3-year premotor phase with autonomic dysfunction, including orthostatic hypotension and erectile dysfunction prior to the onset of parkinsonism or ataxia in multiple system atrophy (162). Premotor Parkinson disease may have similar features, but cardiac sympathetic denervation and hyposmia are not seen in premotor multiple system atrophy. There is a single case report of open bladder neck during storage phase of the bladder as visualized on urodynamics, which preceded the development of generalized motor symptoms of multiple system atrophy (272).

Nerve conduction and EMG studies may show subclinical polyneuropathy in multiple system atrophy. External urethral sphincter EMG shows denervation in almost all patients with multiple system atrophy (167), but not in Parkinson disease or in other cerebellar degenerations (108; 253). The ability of this procedure to distinguish multiple system atrophy from Parkinson disease has, however, been disputed (68), and false positives arise from many nonneurologic causes of sphincter denervation, such as multiparity or pelvic surgery.

Cutaneous phosphorylated alpha-synuclein was found in 98.2% (54 of 55) of patients with multiple system atrophy in a study by Gibbons and colleagues (67). Cutaneous phosphorylated alpha-synuclein testing is beginning to be commercially available in the United States.

Management

Drug treatment: Parkinsonian symptoms. Available treatments are primarily symptomatic (51). Although estimates vary, about 30% to 40% of patients with multiple system atrophy may be responsive to levodopa (32). Facial dystonia occurs more frequently than limb dyskinesias with levodopa therapy. Levodopa therapy may worsen orthostatic hypotension (252; 32). Treatment may be initiated with carbidopa/levodopa 25/100 half to one tablet twice a day and increased every few days to efficacy or side effects. Patients with multiple system atrophy may require and tolerate far larger dosages than patients with Parkinson disease. High-dose levodopa therapy has been found to be nontoxic in a transgenic mouse multiple system atrophy model (219). Ancillary antiparkinsonian agents have not added significantly to the efficacy of levodopa, but adequate studies are lacking. In a double-blind 48-week study, treatment of MSA-P with rasagiline did not show a significant benefit (173).

Lifestyle management: orthostatic hypotension. Treatment of symptomatic orthostatic hypotension starts with sodium and volume repletion unless the patient is at risk of congestive heart failure or renal insufficiency. Patients with multiple system atrophy and dysautonomia should be informed that the frequent recommendation to minimize dietary sodium does not necessarily apply to them. Drinking 350 mL of tap water once daily in the early morning demonstrated a benefit in treating orthostatic hypotension in a group of patients with multiple system atrophy without any adverse effects (39). Four hundred and fifty milliliters of clear water ingestion was confirmed to have a pressor effect in another study of orthostatic insufficiency, but eating clear soup seemed to have a postprandial hypotensive effect (271).

Ancillary measures such as pressure stockings to increase central venous volume and elevating the head of the bed 6 inches to increase renin secretion may also be attempted, but often prove uncomfortable. It is also useful to avoid extreme heat with its reflex peripheral vasodilation and to avoid overeating and straining at stool, which increase vagal activity.

Droxidopa has been shown to be effective for neurogenic orthostatic hypotension in a double-blind trial (101). Typical starting dosage is 100 mg TID titrated in 100 mg increments every 24 to 48 hours up to a maximum dosage of 600 mg TID.

The mineralocorticoid fludrocortisone may be started at 0.1 mg daily and increased to a maximum of four tablets per day in two divided doses, given with fluid repletion. Midodrine, an alpha-adrenergic agonist, is a good alternative (94). Treatment starts with 2.5 mg three times a day increasing to 10 mg three times a day. Supine hypertension is an uncommon but important adverse effect that may be lessened by raising the head of the bed. If these drugs are unsuccessful, inhibition of vasodilator prostaglandin synthesis may be initiated with indomethacin 25 mg three times a day with meals increasing to 50 mg three times a day. Alternatives include the alpha-adrenergic agonist clonidine 0.1 mg twice a day increasing to 0.3 mg twice a day, and the peripheral vasoconstrictors ephedrine starting at 25 mg three times a day and propranolol starting at 20 mg twice a day.

Pyridostigmine has been found to ameliorate the hypotension of multiple system atrophy without causing supine hypertension, at least after a single 60 mg dose (208).

Drug treatment: urological complaints. Urinary frequency or incontinence may respond to a peripherally acting anticholinergic agent such as oxybutynin 5 to 10 mg at bedtime, tolterodine 2 mg at bedtime, or propantheline 15 to 30 mg at bedtime, if the pathophysiology is detrusor hyperreflexia. However, anticholinergic treatment may worsen the constipation of multiple system atrophy. The impotence of multiple system atrophy may respond to yohimbine 5.6 mg one to three times daily (182). Sildenafil, although efficacious, often exacerbates the orthostatic hypotension of multiple system atrophy (87).

Drug treatment: hallucinations. The hallucinations caused by dopaminergic therapeutic agents usually respond to clozapine 6.25 to 50 mg or quetiapine 25 to 75 mg at bedtime. These must be used cautiously in patients with hypotension. All patients receiving clozapine must be monitored for agranulocytosis with weekly white blood cell counts.

Ataxia. There is no known treatment for the ataxia of multiple system atrophy, olivopontocerebellar atrophy type.

Associated sleep disorders and respiratory complaints. Rapid eye movement behavior disorder usually responds well to clonazepam 0.5 mg at bedtime. Patients with multiple system atrophy have a higher risk of obstructive sleep apnea (66). Central apnea due to degeneration of pontomedullary respiratory centers may be masked by untreated obstructive sleep apnea (222). Nocturnal stridor (226) due to vocal cord paralysis and possible excessive adductor activation (243) is treated with continuous positive airway pressure (CPAP) (202).

Laryngoscopy under anesthesia may be useful for evaluating upper airway obstruction in multiple system atrophy (203). Tremulous arytenoid movements are a marker of severity of glottic stenosis, which worsens as the disease progresses (160).

Stridor presents controversies in prognosis and management, as the long-term survival value of interventions for stridor is unclear. According to a consensus statement by Cortelli and colleagues, the prognostic value of stridor is uncertain (Cortelli at al 2019). CPAP ventilation during sleep can be useful for symptomatic control of stridor and should be considered as a first-line treatment. If stridor occurs during wakefulness or CPAP is not tolerated, tracheostomy should be considered (91). The consensus statement cites tracheostomy as being effective in symptomatic control of stridor and may be required for severe stridor (35), but sudden death may occur in a subset of patients, even with tracheostomy (223).

Gastrostomy and tube feeding may be necessary in later stages of the disease (142).

Surgical treatment. Deep brain stimulation of the internal pallidum remains ineffective for multiple system atrophy and may even be harmful (116).

Experimental treatment. Intravenous immunoglobulin therapy has no effect on multiple system atrophy (146).

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been found to inhibit the formation of alpha-synuclein fibrils, which are involved in the pathogenesis of multiple system atrophy and could serve as a potential drug development target for multiple system atrophy treatment (83). Fibril formation is also inhibited by nicotine (156). The Unified Multiple System Atrophy Rating Scale (UMSARS) has been evaluated as an outcome measure to be used in therapeutic trials (252; 134). The UMSARS Motor Examination score, which has been demonstrated to have satisfactory intrarater reliability, seems to be the best outcome measure for future therapeutic trials (113). Pontine and cerebellar atrophy rates on MRI can also serve as outcome measures (166). The PDQ-39 questionnaire, a disease-specific quality-of-life instrument for patients with Parkinson disease, has only limited validity in multiple system atrophy (196). A multiple system atrophy health-related quality-of-life scale (MSA-QoL) has been reported to have good potential for use in clinical trials (197). A prospective, 48-week, randomized, double-blind, multinational study failed to show a clinical effect of minocycline on symptom severity (45). More studies of the serotonergic system may also provide important insights due to reports of serotonergic depletion in ventrolateral medulla as well as a possible motor symptoms benefit from paroxetine (61; 223).

In a transgenic mouse model of multiple system atrophy based on 3-nitropropionic acid intoxication, rasagiline was found to be neuroprotective (220). A clinical trial for rasagiline in multiple system atrophy is currently ongoing. Therapies with rifampicin and autologous mesenchymal stem cells are also being investigated (254). Rifampicin failed to slow progression of autonomic deficits over a 12-month period (130; 207). A small double-blind trial of 33 patients with MSA-C treated with autologous stem cells showed clinical improvement, but there was a safety concern about cerebral ischemic lesions (56). A global MSA registry (GLOMSAR) was created to assist with research endeavors (56). Reduction of alpha-synuclein and suppression of microglial activation by minocycline or myeloperoxidase inhibition have shown benefit in animal models, but caution needs to be employed when extrapolating these results to potential for human disease modification (221; 111). In a mouse model, CLR01, which reduces alpha-synuclein oligomer formation and promotes destruction of formed oligomers, may reduce alpha-synuclein pathology (128). VX‐765, a caspase‐1 inhibitor precursor, and anle138b, an alpha-synuclein aggregation inhibitor that targets oligomeric α‐synuclein, are being tested in animal models (135). Current research also focuses on alpha-synuclein clearance via nilotinib or immunotherapy methods as well as alpha-synuclein suppression via antisense oligonucleotides, such as BIIB101 (120).

Outcomes

Please see specific outcome and side effect discussion in relation to particular treatment modalities above.

References

01: Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007a;28(5):742-7. PMID 16678934
02: Abdo WF, van de Warrenburg BP, Kremer HP, Bloem BR, Verbeek MM. CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy. Parkinsonism Relat Disord 2007b;13(8):480-2. PMID 17448720
03: Abele M, Burk K, Schols L, et al. The aetiology of sporadic adult-onset ataxia. Brain 2002;125(Pt 5):961-8. PMID 11960886
04: Abele M, Minnerop M, Urbach H, Specht K, Klockgether T. Sporadic adult onset ataxia of unknown etiology : a clinical, electrophysiological and imaging study. J Neurol 2007;254(10):1384-9. PMID 17934884
05: Adams RD, Salam-Adams M. Striatonigral degeneration. In: Vinken PJ, Bruyn GW, Klawans HL, editors. Extrapyramidal disorders. Handbook of clinical neurology. Vol. 49. Amsterdam: Elsevier, 1986:205-12.
06: Adams RD, van Bogaert L, van der Eecken H. Striato-nigral degeneration. J Neuropathol Exp Neurol 1964;23:584-608. PMID 14219099
07: Albuquerque AV, Freitas MR, Cincinatus D, Harouche MB. Clinical-radiological correlation. Report of two cases. Arq Neuropsiquiatr 2007;65(2B):512-5. PMID 17665026
08: Anderson T, Luxon L, Quinn N, Daniel S, Marsden CD, Bronstein A. Oculomotor function in multiple system atrophy: clinical and laboratory features in 30 patients. Mov Disord 2008;23(7):977-84. PMID 18383533
09: Armstrong RA. Visual signs and symptoms of Parkinson's disease. Clin Exp Optom 2008;91(2):129-38. PMID 18271776
10: Armstrong RA, Cairns NJ, Lantos PL. A quantitative study of the pathological changes in white matter in multiple system atrophy. Neuropathology 2007;27(3):221-7. PMID 17645235
11: Asahina M, Low DA, Mathias CJ, et al. Skin temperature of the hand in multiple system atrophy and Parkinson's disease. Parkinsonism Relat Disord 2013;19(5):560-2. PMID 23453042
12: Asi YT, Ling H, Ahmed Z, Lees AJ, Revesz T, Holton JL. Neuropathological features of multiple system atrophy with cognitive impairment. Mov Disord 2014;29(7):884-8. PMID 24752994
13: Baba Y, Uitti RJ, Boylan KB, et al. Aprataxin (APTX) gene mutations resembling multiple system atrophy. Parkinsonism Relat Disord 2007;13(3):139-42. PMID 17049295
14: Balas M, Balash Y, Giladi N, Gurevich T. Cognition in multiple system atrophy: neuropsychological profile and interaction with mood. J Neural Transm 2010;117(3):369-75. PMID 20091064
15: Barca E, Kleiner G, Tang G, et al. Decreased coenzyme Q10 levels in multiple system atrophy cerebellum. J Neuropathol Exp Neurol 2016;75(7):663-72. PMID 27235405
16: Batla A, De Pablo-Fernandez E, Erro R, et al. Young-onset multiple system atrophy: clinical and pathological features. Mov Disord 2018;33(7):1099-107. PMID 30153390
17: Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urology 1994;151:1336-41. PMID 8158782
18: Benarroch EE, Schmeichel AM, Sandroni P, Parisi JE, Low PA. Rostral raphe involvement in Lewy body dementia and multiple system atrophy. Acta Neuropathol 2007;114(3):213-20. PMID 17639427
19: Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997;48:384-93. PMID 9040727
20: Bjornsdottir A, Gudmundsson G, Blondal H, Olafsson E. Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. J Neurol Neurosurg Psychiatry 2013;84(2):136-40. PMID 23192520
21: Bordet R, Benhadjali J, Destee A, Hurtevent JF, Bourriez JL, Guieu JD. Sympathetic skin response and R-R interval variability in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord 1996;11(3):268-72. PMID 8723143
22: Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997;49:1284-8. PMID 9371909
23: Brooks DJ, Seppi K; Neuroimaging Working Group on MSA. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009;24(7):949-64. PMID 19306362
24: Bukhatwa S, Zeng BY, Rose S, Jenner P. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Brain Res 2010;1326:174-83. PMID 20176003
25: Burk K, Skalej M, Dichgans J. Pontine MRI hyperintensities ("the cross sign") are not pathognomonic for multiple system atrophy (MSA). Mov Disord 2001;16(3):535. PMID 11391754
26: Calandra-Buonaura G, Guaraldi P, Sambati L, et al. Multiple system atrophy with prolonged survival: is late onset of dysautonomia the clue. Neurol Sci 2013;34(10):1875-8. PMID 23728718
27: Campese N, Fanciulli A, Stefanova N, Haybaeck J, Kiechl S, Wenning GK. Neuropathology of multiple system atrophy: Kurt Jellinger’s legacy. J Neural Transm (Vienna) 2021;128:1481-94. PMID 34319460
28: Cho JW, Jeon BS, Jeong D, et al. Association between parkinsonism and participation in agriculture in Korea. J Clin Neurol 2008a;4(1):23-8. PMID 19513320
29: Cho JW, Kim SY, Park SS, Jeon BS. Spinocerebellar ataxia type 12 was not found in Korean Parkinsonian patients. Can J Neurol Sci 2008b;35(4):488-90. PMID 18973067
30: Claassen DO, Adler CH, Hewitt LA, Gibbons C. Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers. BMC Neurol 2018;18(1):125. PMID 30144800
31: Colosimo C, Morgante L, Antonini A, et al. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol 2010;257(1):5-14. PMID 19669613
32: Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Mov Disord 2007;22(15):2141-8. PMID 17534959
33: Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord 2010;16(2):142-5. PMID 19647470
34: Coon EA, Sletten DM, Suarez MD, et al. Clinical features and autonomic testing predict survival in multiple system atrophy. Brain 2015;138(Pt 12):3623-31. PMID 26369944
35: Cortelli P, Calandra-Buonaura G, Benarroch EE, et al. Stridor in multiple system atrophy: consensus statement on diagnosis, prognosis, and treatment. Neurology 2019;93(14):630-9. PMID 31570638
36: Cosottini M, Ceravolo R, Faggioni L, et al. Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. Acta Neurol Scand 2007;116(1):37-42. PMID 17587253
37: Cykowski MD, Coon EA, Powell SZ, et al. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain 2015;138(Pt 8):2293-309. PMID 25981961
38: De Cock VC, Debs R, Oudiette D, et al. The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy. Brain 2011;134(Pt 3):856-62. PMID 21310729
39: Deguchi K, Ikeda K, Sasaki I, et al. Effects of daily water drinking on orthostatic and postprandial hypotension in patients with multiple system atrophy. J Neurol 2007a;254(6):735-40. PMID 17420927
40: Deguchi K, Ikeda K, Shimamura M, et al. Assessment of autonomic dysfunction of multiple system atrophy with laryngeal abductor paralysis as an early manifestation. Clin Neurol Neurosurg 2007b;109(10):892-5. PMID 17826894
41: Dejerine J, Thomas A. L'atrophie olivopontocerebelleuse. Nouv Iconogr Salpet 1900;13:330-70.
42: Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010;119(6):703-13. PMID 20229352
43: Deng H, Liang H, Jankovic J. F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol 2013;70(1):20-4. PMID 23318512
44: Dickson DW, Liu WK, Hardy J, et al. Widespread alterations in alpha-synuclein in multiple system atrophy. Am J Pathol 1999;155:1241-51. PMID 10514406
45: Dodel R, Spottke A, Gerhard A, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010;25(1):97-107. PMID 20014118
46: Doherty KM, Warner TT, Lees AJ. Late onset ataxia: MSA-C or SCA 17. A gene penetrance dilemma. Mov Disord 2014;29(1):36-8. PMID 24343983
47: Du J, Wang T, Huang P, et al. Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy. Parkinsonism Relat Disord 2018;57:58-62. PMID 30093363
48: Dutta S, Hornung S, Kruyatidee A, et al. α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy. Acta Neuropathol 2021;142:495-511. PMID 33991233
49: Eckert T, Van Laere K, Tang C, et al. Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 2007;34(4):496-501. PMID 17096095
50: Egami N, Inoue A, Osanai R, Kitahara N, Kaga K. Vocal cord abductor paralysis in multiple system atrophy: a case report. Acta Otolaryngol Suppl 2007;(559):164-7. PMID 18340590
51: Esper CD, Factor SA. Current and future treatments in multiple system atrophy. Curr Treat Options Neurol 2007;9(3):210-23. PMID 17445499
52: Eusebio A, Azulay JP, Witjas T, Rico A, Attarian S. Assessment of cortico-spinal tract impairment in multiple system atrophy using transcranial magnetic stimulation. Clin Neurophysiol 2007;118(4):815-23. PMID 17317305
53: Fabbrini G, Merello M, Evans AH, Lees AJ, Holton J, Williams DR. Progressive parkinsonism, oculomotor abnormalities and autonomic dysfunction: clinicopathological case. Mov Disord 2011;26(3):424-9. PMID 21462257
54: Fanciulli A, Goebel G, Lazzeri G, et al. Early distinction of Parkinson-variant multiple system atrophy from Parkinson's disease. Mov Disord 2019a;34(3):440-1. PMID 30788854
55: Fanciulli A, Goebel G, Lazzeri G, et al. Urinary retention discriminates multiple system atrophy from Parkinson's disease. Mov Disord 2019b;34(12):1926-8. PMID 31710392
56: Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med 2015;372(14):1375-6. PMID 25830435
57: Figueroa JJ, Singer W, Parsaik A, et al. Multiple system atrophy: prognostic indicators of survival. Mov Disord 2014;29(9):1151-7. PMID 24909319
58: Finke C, Siebert E, Plotkin M, Wenning GK, Reuter U. Multiple system atrophy masking multiple sclerosis. Clin Neurol Neurosurg 2010;112(1):59-61. PMID 19735973
59: Freilich S, Goff EA, Malaweera AS, et al. Sleep architecture and attenuated heart rate response to arousal from sleep in patients with autonomic failure. Sleep Med 2010;11(1):87-92. PMID 19962940
60: Friedrich C, Rudiger H, Schmidt C, et al. Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. J Neural Transm 2008;115(11):1527-36. PMID 18806923
61: Friess E, Kuempfel T, Modell S, et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord 2006;12(7):432-7. PMID 16769235
62: Fujimori J, Tatewaki Y, Shimizu H, Kimura I, Hisanaga K. [Degeneration of ponto-cerebellar tract visualized by diffusion tensor imaging in multiple system atrophy] [Article in Japanese]. Rinsho Shinkeigaku 2011;51(4):271-4. PMID 21595297
63: Fukushima T, Asahina M, Fujinuma Y, et al. Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy. J Neurol 2013;260(2):475-83. PMID 22983428
64: Furiya Y, Hirano M, Kurumatani N, et al. alpha-1-Antichymotrypsin gene polymorphism and susceptibility to multiple system atrophy (MSA). Brain Res Mol Brain Res 2005;138:178-81. PMID 15907346
65: Gai WP, Power JH, Blumbergs PC, Blessing WW. Multiple-system atrophy: a new alpha-synuclein disease. Lancet 1998;352:547-8. PMID 9716068
66: Gama RL, Tavora DG, Bomfim RC, Silva CE, de Bruin VM, de Bruin PF. Sleep disturbances and brain MRI morphometry in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy - a comparative study. Parkinsonism Relat Disord 2010;16(4):275-9. PMID 20185356
67: Gibbons CH, Levine T, Adler C, et al. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA 2024;331(15):1298-306. PMID 38506839
68: Giladi N, Simon ES, Korczyn AD, et al. Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson’s disease. Muscle Nerve 2000;23:731-4. PMID 10797396
69: Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163(1):94-8. PMID 10223419
70: Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71(9):670-6. PMID 18725592
71: Giordano I, Harmuth F, Jacobi H, et al. Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. Neurology 2017;89(10):1043-9. PMID 28794257
72: Goh YY, Saunders E, Pavey S, et al. Multiple system atrophy. Pract Neurol 2023;23(3):208-21. PMID 36927875
73: Goldman JS, Quinzii C, Dunning-Broadbent J, et al. Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. JAMA Neurol 2014;71(6):771-4. PMID 24733620
74: Goldstein DS. Cardiac ectopy in chronic autonomic failure. Clin Auton Res 2010;20(2):85-92. PMID 20012145
75: Goldstein DS, Holmes C, Bentho O, et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008;14(8):600-7. PMID 18325818
76: Gomez-Esteban JC, Tijero B, Ciordia R, et al. Factors influencing the symmetry of Parkinson's disease symptoms. Clin Neurol Neurosurg 2010;112(4):302-5. PMID 20083340
77: Guevara CA, Blain CR, Stahl D, Lythgoe DJ, Leigh PN, Barker GJ. Quantitative magnetic resonance spectroscopic imaging in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Eur J Neurol 2010;17(9):1193-202. PMID 20402762
78: Gupta D, Saini J, Kesavadas C, Sarma PS, Kishore A. Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology 2010;52(12):1087-94. PMID 20358367
79: Hara K, Momose Y, Tokiguchi S, et al. Multiplex families with multiple system atrophy. Arch Neurol 2007;64(4):545-51. PMID 17420317
80: Hellmann MA, Melamed E, Steinmetz AP, Djaldetti R. Unilateral lower limb rest tremor is not necessarily a presenting symptom of Parkinson’s disease. Mov Disord 2010;25(7):924-7. PMID 20198647
81: Herbert MK, Eeftens JM, Aerts MB, et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord 2014;20(1):112-5. PMID 24075122
82: Hirano S, Shinotoh H, Arai K, et al. PET study of brain acetylcholinesterase in cerebellar degenerative disorders. Mov Disord 2008;23(8):1154-60. PMID 18412283
83: Hirohata M, Ono K, Morinaga A, Yamada M. Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. Neuropharmacology 2008;54(3):620-7. PMID 18164319
84: Honjo Y, Shirakashi Y, Kawamoto Y, Akiguchi I. Anti-DARPP32 antibody-immunopositive inclusions in the brain of patients with multiple system atrophy. Clin Neuropathol 2008;27(5):309-16. PMID 18808062
85: Huang Y, Song YJ, Murphy K, et al. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathol 2008;116(6):639-46. PMID 18936941
86: Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992;55:1009-13. PMID 1469394
87: Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-4. PMID 11511713
88: Imrich R, Eldadah BA, Bentho O, et al. Attenuated pre-ejection period response to tyramine in patients with cardiac sympathetic denervation. Ann N Y Acad Sci 2008;1148:486-9. PMID 19120145
89: Iodice V, Lipp A, Ahlskog JE, et al. Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests. J Neurol Neurosurg Psychiatry 2012;83(4):453-9. PMID 22228725
90: Iranzo A. Management of sleep-disordered breathing in multiple system atrophy. Sleep Med 2005;6(4):297-300. PMID 15978513
91: Iranzo A. Sleep and breathing in multiple system atrophy. Curr Treat Options Neurol 2007;9(5):347-53. PMID 17716598
92: Iranzo A, Santamaria J, Rye DB, et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005;65:247-52. PMID 16043794
93: Ito M, Watanabe H, Kawai Y, et al. Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J Neurol Neurosurg Psychiatry 2007;78(7):722-8. PMID 17353258
94: Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am J Med 1993;95(1):38-48. PMID 7687093
95: Jellinger K. Neuropathology. In: Wenning GK, Fanciulli A, editors. Multiple system atrophy. Springer-Verlag Wien, 2014:17-56.
96: Jellinger KA, Lantos PL. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol 2010;119(6):657-67. PMID 20309568
97: Jeon BS, Farrer MJ, Bortnick SF, Korean Canadian Alliance on Parkinson’s Disease and Related Disorders. Mutant COQ2 in multiple-system atrophy. N Engl J Med 2014;371(1):80. PMID 24988567
98: Kaji S, Maki T, Ishimoto T, Yamakado H, Takahashi R. Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions. Transl Neurodegener 2020;9:7. PMID 32095235
99: Kamm C, Healy DG, Quinn NP, et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 2005;128:1855-60. PMID 15947063
100: Kataoka H, Tonomura Y, Taoka T, Ueno S. Signal changes of superior cerebellar peduncle on fluid-attenuated inversion recovery in progressive supranuclear palsy. Parkinsonism Relat Disord 2008;14(1):63-5. PMID 17481936
101: Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014;83(4):328-35. PMID 24944260
102: Kawai Y, Suenaga M, Takeda A, et al. Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology 2008;70(16 Pt 2):1390-6. PMID 18413566
103: Kawamoto Y, Kobayashi Y, Suzuki Y, et al. Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with alpha-synucleinopathies. J Neuropathol Exp Neurol 2008;67(10):984-93. PMID 18800009
104: Kiely AP, Asi YT, Kara E, et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy. Acta Neuropathol 2013;125(5):753-69. PMID 23404372
105: Kim HJ, Jeon BS. Multiple system atrophy with prolonged survival. Mov Disord 2012;27(14):1834. PMID 23225574
106: Kim HJ, Jeon BS, Lee JY, Yun JY, Kim YE, Paek SH. Young-onset multiple system atrophy. J Neurol Sci 2012;319(1-2):168-70. PMID 22607745
107: Kim HW, Kim JS, Oh M, et al. Different loss of dopamine transporter according to subtype of multiple system atrophy. Eur J Nucl Med Mol Imaging 2016;43(3):517-25. PMID 26384682
108: Kirby R, Fowler C, Gosling F, Bannister R. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol Neurosurg Psychiatry 1986;49:554-62. PMID 3711918
109: Koga S, Aoki N, Uitti RJ, et al. When DLB, PD, and PSP masquerade as MSA: An autopsy study of 134 patients. Neurology 2015;85(5):404-12. PMID 26138942
110: Kollensperger M, Geser F, Seppi K, et al. Red flags for multiple system atrophy. Mov Disord 2008;23(8):1093-9. PMID 18442131
111: Krismer F, Seppi, K, Stefanova N, Wenning GK. Toward disease modification in multiple system atrophy: pitfalls, bottlenecks, and possible remedies. Mov Disord 2016;31(2):235-40. PMID 26813934
112: Krismer F, Seppi K, Wenning GK, et al. Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. Parkinsonism Relat Disord 2019;58:23-7. PMID 30145124
113: Krismer F, Seppi K, Tison F, et al. The Unified Multiple System Atrophy Rating Scale: intrarater reliability. Mov Disord 2012;27(13):1683-5. PMID 23114993
114: Kuo SH, Quinzii CM. Coenzyme Q10 as a peripheral biomarker for multiple system atrophy. JAMA Neurol 2016;73(8):917-9. PMID 27367485
115: Kwon KY, Choi CG, Kim JS, Lee MC, Chung SJ. Diagnostic value of brain MRI and 18F-FDG PET in the differentiation of Parkinsonian-type multiple system atrophy from Parkinson's disease. Eur J Neurol 2008;15(10):1043-9. PMID 18717730
116: Lambrecq V, Krim E, Meissner W, Guehl D, Tison F. [Deep-brain stimulation of the internal pallidum in multiple system atrophy.] Rev Neurol (Paris) 2008;164(4):398-402. PMID 18439935
117: Lastres-Becker I, Rub U, Auburger G. Spinocerebellar ataxia 2 (SCA2). Cerebellum 2008;7(2):115-24. PMID 18418684
118: Laurens B, Constantinescu R, Freeman R, et al. Fluid biomarkers in multiple system atrophy: A review of the MSA biomarker initiative. Neurobiol Dis 2015;80:29-41. PMID 25982836
119: Lee JY, Yun JY, Shin CW, Kim HJ, Jeon BS. Putaminal abnormality on 3-T magnetic resonance imaging in early parkinsonism-predominant multiple system atrophy. J Neurol 2010;257(12):2065-70. PMID 20652301
120: Lemos M, Wenning GK, Stefanova N. Current experimental disease-modifying therapeutics for multiple system atrophy. J Neural Transm (Vienna) 2021;128(10):1529-43. PMID 34398313
121: Lin DJ, Hermann KL, Schmahmann JD. Multiple system atrophy of the cerebellar type: clinical state of the art. Mov Disord 2014;29(3):294-304. PMID 24615754
122: Lin IS, Wu RM, Lee-Chen GJ, Shan DE, Gwinn-Hardy K. The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment. Parkinsonism Relat Disord 2007;13(4):246-9. PMID 16793320
123: Lincoln SJ, Ross OA, Milkovic NM, et al. Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy. Parkinsonism Relat Disord 2007;13(6):340-2. PMID 17291816
124: Linder J, Stenlund H, Forsgren L. Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study. Mov Disord 2010;25(3):341-8. PMID 20108376
125: Lipp A, Sandroni P, Ahlskog JE, Maraganore DM, Shults CW, Low PA. Calf venous compliance in multiple system atrophy. Am J Physiol Heart Circ Physiol 2007;293(1):H260-5. PMID 17337590
126: Lipp A, Sandroni P, Ahlskog JE, et al. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol 2009;66(6):742-50. PMID 19506134
127: Lipp A, Schmelzer JD, Low PA, Johnson BD, Benarroch EE. Ventilatory and cardiovascular responses to hypercapnia and hypoxia in multiple-system atrophy. Arch Neurol 2010;67(2):211-6. PMID 20142529
128: Lopez-Cuina M, Foubert-Samier A, Tison F, Meissner WG. Present and future of disease-modifying therapies in multiple system atrophy. Auton Neurosci 2018;211:31-8. PMID 29311010
129: Low PA, Reich SG, Jankovic J, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 2015;14(7):710-9. PMID 26025783
130: Low PA, Robertson D, Gilman S, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13(3):268-75. PMID 24507091
131: Mabuchi N, Hirayama M, Koike Y, et al. Progression and prognosis in pure autonomic failure (PAF): comparison with multiple system atrophy. J Neurol Neurosurg Psychiatry 2005;76:947-52. PMID 15965200
132: Marini C, di Poggio MB, Pomposelli E, et al. Whole body and cardiac metaiodobenzylguanidine kinetics in Parkinson disease and multiple system atrophy: implications for the diagnostic role of imaging. Clin Nucl Med 2010;35(5):311-6. PMID 20395701
133: Martinez-Rodriguez JE, Seppi K, Cardozo A, et al. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. Mov Disord 2007;22(12):1822-4. PMID 17659646
134: May S, Gilman S, Sowell BB, et al. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord 2007;22(16):2371-7. PMID 17914727
135: Meissner WG, Fernagut PO, Dehay B, et al. Multiple system atrophy: recent developments and future perspectives. Mov Disord 2019;34(11):1629-42. PMID 31692132
136: Miller VM, Kalaria RN, Hall R, Oakley AE, Kenny RA. Medullary microvessel degeneration in multiple system atrophy. Neurobiol Dis 2007;26(3):615-22. PMID 17466525
137: Minnerop M, Specht K, Ruhlmann J, et al. Voxel-based morphometry and voxel-based relaxometry in multiple system atrophy-a comparison between clinical subtypes and correlations with clinical parameters. Neuroimage 2007;36(4):1086-95. PMID 17512219
138: Miyatake S, Mochizuki H, Naka T, et al. Brain volume analyses and somatosensory evoked potentials in multiple system atrophy. J Neurol 2010;257(3):419-25. PMID 19789939
139: Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 2013;369(3):233-44. PMID 23758206
140: Munschauer FE, Loh L, Bannister R, Newsom-Davis J. Abnormal respiration and sudden death during sleep in multiple system atrophy with autonomic failure. Neurology 1990;40:677-9. PMID 2320245
141: Muqit MM, Mort D, Miskiel KA, Shakir RA. "Hot cross bun" sign in a patient with parkinsonism secondary to presumed vasculitis. J Neurol Neurosurg Psychiatry 2001;71(4):565-6. PMID 11601421
142: Nagaoka U, Shimizu T, Matsukura T, Takeda M. [Nutritional problems in multiple system atrophy--necessity of early tube feeding and caloric restriction at the advanced stage.] Rinsho Shinkeigaku 2010;50(3):141-6. PMID 20235481
143: Nagata T, Kamei H, Furuya K, Fujii N, Noda K, Iwaki T. [Pathological study on abducent paralysis of the vocal cord in a patient having multiple system atrophy with nasogastric intubation.] Rinsho Shinkeigaku 2007;47(6):340-3. PMID 17633106
144: Nandi D, Jenkinson N, Stein J, Aziz T. The pedunculopontine nucleus in Parkinson's disease: primate studies. Br J Neurosurg 2008;22 Suppl 1:S4-8. PMID 19085345
145: Nanri K, Koizumi K, Mitoma H, et al. Classification of cerebellar atrophy using voxel-based morphometry and SPECT with an easy Z-score imaging system. Intern Med 2010;49(6):535-41. PMID 20228587
146: Nanri K, Okita M, Takeguchi M, et al. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med 2009;48(10):783-90. PMID 19443972
147: Nee LE, Gomez MR, Dambrosia J, Bale S, Eldridge R, Polinsky RJ. Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res 1991;1(1):9-13. PMID 1821673
148: Nicoletti G, Rizzo G, Barbagallo G, et al. Diffusivity of cerebellar hemispheres enables discrimination of cerebellar or parkinsonian multiple system atrophy from progressive supranuclear palsy-richardson syndrome and Parkinson disease. Radiology 2013;267(3):843-50. PMID 23329659
149: Nishimura M, Kawakami H, Komure O, et al. Contribution of the interleukin-1beta gene polymorphism in multiple system atrophy. Mov Disord 2002;17(4):808-11. PMID 12210881
150: Nocker M, Seppi K, Donnemiller E, et al. Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [(123)I]β-CIT SPECT. Eur J Nucl Med Mol Imaging 2012;39:1012-20. PMID 22460689
151: Ogaki K, Fujioka S, Heckman MG, et al. Analysis of COQ2 gene in multiple system atrophy. Mol Neurodegener 2014;9:44. PMID 25373618
152: Ogaki K, Heckman MG, Koga S, et al. Association study between multiple system atrophy and TREM2 p.R47H. Neurol Genet 2018;4(4):e257. PMID 30109269
153: Okawa M, Miwa H, Kajimoto Y, et al. Transcranial sonography of the substantia nigra in Japanese patients with Parkinson's disease or atypical parkinsonism: clinical potential and limitations. Intern Med 2007;46(18):1527-31. PMID 17878638
154: Okuma Y, Fujishima K, Miwa H, Mori H, Mizuno Y. Myoclonic tremulous movements in multiple system atrophy are a form of cortical myoclonus. Mov Disord 2005;252:91-6. PMID 15593313
155: Okuzumi A, Hatano T, Matsumoto G, et al. Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 2023;29(6):1448-55. PMID 37248302
156: Ono K, Hirohata M, Yamada M. Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases. Exp Neurol 2007;205(2):414-24. PMID 17425956
157: Orimo S. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies.] Rinsho Shinkeigaku 2008a;48(11):831-4. PMID 19198094
158: Orimo S, Uchihara T, Nakamura A, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008b;131(Pt 3):642-50. PMID 18079166
159: Ozawa T. Morphological substrate of autonomic failure and neurohormonal dysfunction in multiple system atrophy: impact on determining phenotype spectrum. Acta Neuropathol 2007;114(3):201-11. PMID 17593377
160: Ozawa T, Shinoda H, Tomita M, Shimohata T, Nakayama H, Nishizawa M. Tremulous arytenoid movements predict severity of glottic stenosis in multiple system atrophy. Mov Disord 2010;25(10):1418-23. PMID 20310045
161: Paleologou KE, Oueslati A, Shakked G, et al. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 2010;30(9):3184-98. PMID 20203178
162: Palma JA, Kaufmann H. Autonomic disorders predicting Parkinson’s disease. Parkinsonism Relat Disord 2014;20 Suppl 1:S94-8. PMID 24262198
163: Papp M, Kahn J, Lantos P. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94:79-100. PMID 2559165
164: Parkkinen L, Hartikainen P, Alafuzoff I. Abundant glial alpha-synuclein pathology in a case without overt clinical symptoms. Clin Neuropathol 2007;26(6):276-83. PMID 18232593
165: Parvizi J, Joseph J, Press DZ, Schmahmann JD. Pathological laughter and crying in patients with multiple system atrophy-cerebellar type. Mov Disord 2007;22(6):798-803. PMID 17290465
166: Paviour DC, Price SL, Lees AJ, Fox NC. MRI derived brain atrophy in PSP and MSA-P. Determining sample size to detect treatment effects. J Neurol 2007;254(4):478-81. PMID 17401522
167: Paviour DC, Williams D, Fowler CJ, Quinn NP, Lees AJ. Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy. A retrospective study with pathological diagnosis. Mov Disord 2005;20(11):1425-30. PMID 16007638
168: Pavy-Le Traon A, Piedvache A, Perez-Lloret S, et al. New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. J Neurol Neurosurg Psychiatry 2016;87(5):554-61. PMID 25977316
169: Pellecchia MT, Longo K, Manfredi M, et al. The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms. Mov Disord 2008;23(2):190-4. PMID 18044703
170: Petrovic IN, Ling H, Asi Y, et al. Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord 2012;27(9):1186-90. PMID 22806758
171: Pietzarka K, Reimann M, Schmidt C, et al. The cold hand sign in multiple system atrophy: skin perfusion revisited. J Neural Transm 2010;117(4):475-9. PMID 20151311
172: Plazzi G, Corsini R, Provini F, et al. REM sleep behavior disorders in multiple system atrophy. Neurology 1997;48:1094-7. PMID 9109907
173: Poewe W, Seppi K, Fitzer-Attas CJ, et al. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol 2015;14(2):145-52. PMID 25498732
174: Pouclet H, Lebouvier T, Coron E. Analysis of colonic alpha-synuclein pathology in multiple system atrophy. Parkinsonism Relat Disord 2012;18(7):893-5. PMID 22560049
175: Provitera V, Nolano M, Caporaso G, et al. Postganglionic sudomotor denervation in patients with multiple system atrophy. Neurology 2014;82(24):2223-9. PMID 24838791
176: Prusiner SB, Woerman AL, Mordes DA, et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A 2015;112(38):E5308-17. PMID 26324905
177: Punal Rioboo J, Varela Lema L, Serena Puig A, Ruano-Ravina A. [Effectiveness of 123I-ioflupane (DaTSCAN) in the diagnosis of Parkinsonian syndromes. A systematic review.] Rev Esp Med Nucl 2007;26(6):375-84. PMID 18021694
178: Quinn N. Multiple system atrophy--the nature of the beast. J Neurol Neurosurg Psychiatry 1989;Suppl:78-89. PMID 2666581
179: Quinn NP, Luthert P, Honavar M, Marsden CD. Pure akinesia due to Lewy body Parkinson's disease: a case with pathology. Mov Disord 1989;4(1):85-8. PMID 2538728
180: Reimann M, Schmidt C, Herting B, et al. Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm 2010;117(1):69-76. PMID 19763772
181: Richter D, Katsanos AH, Schroeder C, et al. Lentiform nucleus hyperechogenicity in Parkinsonian syndromes: a systematic review and meta-analysis with consideration of molecular pathology. Cells 2019;9(1). PMID 31861253
182: Robertson D, Davis TL. Recent advances in the treatment of orthostatic hypotension. Neurology 1995;45:S26-32. PMID 7746370
183: Ronchi D, Di Biase E, Franco G, et al. Mutational analysis of COQ2 in patients with MSA in Italy. Neurobiol Aging 2016;45:213. PMID 27394078
184: Rusina R, Bourdain F, Matej R. [Multiple system atrophy and Alzheimer’s disease: a case report of a rare association of two neuro-degenerative disorders.] Rev Neurol (Paris) 2007;163(12):1239-41. PMID 18355473
185: Saeed U, Compagnone J, Aviv RI, et al. Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. Transl Neurodegener 2017;6:8. PMID 28360997
186: Sailer A, Scholz SW, Nalls MA, et al. A genome-wide association study in multiple system atrophy. Neurology 2016;87(15):1591-8. PMID 27629089
187: Sakakibara R, Panicker J, Simeoni S, et al. Bladder dysfunction as the initial presentation of multiple system atrophy: a prospective cohort study. Clin Auton Res 2019;29(6):627-31. PMID 30043182
188: Sako W, Murakami N, Izumi Y, Kaji R. The difference in putamen volume between MSA and PD: evidence from a meta-analysis. Parkinsonism Relat Disord 2014;20(8):873-7. PMID 24844749
189: Salazar G, Casas E, Oliveras D, Rando A, Sergio P. Ocular-jaw synkinesia in normal, Parkinson's disease, and multiple system atrophy subjects: Clinical and electrophysiological findings. Clin Neurophysiol 2010;121(1):94-7. PMID 19906558
190: Salvesen L, Winge K, Brudek T, Agander TK, Lokkegaard A, Pakkenberg B. Neocortical neuronal loss in patients with multiple system atrophy: a stereological study. Cereb Cortex 2017;27(1):400-10. PMID 26464477
191: Sato K, Kaji R, Matsumoto S, Goto S. Cell type-specific neuronal loss in the putamen of patients with multiple system atrophy. Mov Disord 2007a;22(5):738-42. PMID 17266045
192: Sato K, Kaji R, Matsumoto S, Nagahiro S, Goto S. Compartmental loss of striatal medium spiny neurons in multiple system atrophy of parkinsonian type. Mov Disord 2007b;22(16):2365-70. PMID 17894336
193: Scholz SW, Houlden H. Author response: a genome-wide associated study in multiple system atrophy. Neurology 2017;88(13):1296-7. PMID 28348123
194: Scholz SW, Houlden H, Schulte C, et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 2009;65(5):610-4. PMID 19475667
195: Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354:1771-5. PMID 10577638
196: Schrag A, Jenkinson C, Selai C, Mathias C, Quinn N. Testing the validity of the PDQ-39 in patients with MSA. Parkinsonism Relat Disord 2007a;13(3):152-6. PMID 17070089
197: Schrag A, Selai C, Mathias C, et al. Measuring health-related quality of life in MSA: the MSA-QoL. Move Disord 2007b;22(16):2332-8. PMID 17914730
198: Schweighauser M, Shi Y, Tarutani A, et al. Structures of α-synuclein filaments from multiple system atrophy. Nature 2020;585(7825):464-9. PMID 32461689
199: Seppi K, Poewe W. Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am 2010;20(1):29-55. PMID 19959017
200: Seppi K, Yekhlef F, Diem A, et al. Progression of parkinsonism in multiple system atrophy. J Neurol 2005;20:158-63. PMID 15654560
201: Sharma M, Wenning G, Kruger R, European Multiple-System Atrophy Study Group. Mutant COQ2 in multiple-system atrophy. N Engl J Med 2014;371(1):80-3. PMID 24988568
202: Shiba K, Isono S, Nakazawa K. Paradoxical vocal cord motion: a review focused on multiple system atrophy. Auris Nasus Larynx 2007;34(4):443-52. PMID 17482397
203: Shimohata T, Shinoda H, Nakayama H, et al. Daytime hypoxemia, sleep-disordered breathing, and laryngopharyngeal findings in multiple system atrophy. Arch Neurol 2007;64(6):856-61. PMID 17562934
204: Shin HY, Kang SY, Yang JH, Kim HS, Lee MS, Sohn YH. Use of the Putamen/Caudate Volume Ratio for Early Differentiation between Parkinsonian Variant of Multiple System Atrophy and Parkinson Disease. J Clin Neurol 2007;3(2):79-81. PMID 19513295
205: Shrivastava A. The hot cross bun sign. Radiology 2007;245(2):606-7. PMID 17940314
206: Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a clinical-pathological study. Arch Neurol 1960;2:511-27. PMID 14446364
207: Singer W, Cheshire W, Fealey R, et al. Randomized trial of rifampicin in MSA: effect on autonomic function. Neurology 2014;82(10):S16.006.
208: Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513-8. PMID 16476804
209: Singer W, Schmeichel A, Goldstein D, et al. Spinal fluid biomarkers for multiple system atrophy – a pilot study. Neurology 2016;86(16):S18.002.
210: Siri C, Duerr S, Canesi M, et al. A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. J Neural Transm 2013;120(4):613-8. PMID 23462799
211: Soares-Fernandes JP, Ribeiro M, Machado A. "Hot cross bun" sign in variant Creutzfeldt-Jakob disease. AJNR Am J Neuroradiol 2009;30(3):E37. PMID 19279286
212: Soma H, Yabe I, Takei A, Fujiki N, Yanagihara T, Sasaki H. Heredity in multiple system atrophy. J Neurol Sci 2006;240:107-10. PMID 16307759
213: Song IU, Yoo I, Chung YA, Jeong J. The value of brain perfusion SPECT for differentiation between mildly symptomatic idiopathic Parkinson's disease and the Parkinson variant of multiple system atrophy. Nucl Med Commun 2015;36(10):1049-54. PMID 26087241
214: Song SK, Lee SK, Lee JJ, et al. Blood-brain barrier impairment is functionally correlated with clinical severity in patients of multiple system atrophy. Neurobiol Aging 2011;32(12)2183-9. PMID 20149484
215: Song YJ, Lundvig DM, Huang Y, et al. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 2007;171(4):1291-303. PMID 17823288
216: Stamelou M, Quinn NP, Bhatia KP. "Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide. Mov Disord 2013;28(9):1184-99. PMID 23720239
217: Stankovic I, Krismer F, Jesic A, et al. Cognitive impairment in multiple system atrophy: a position statement by the neuropsychology task force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord 2014;29(7):857-67. PMID 24753321
218: Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009;8(12):1172-8. PMID 19909915
219: Stefanova N, Kollensperger M, Hainzer M, Cenci A, Poewe W, Wenning GK. High dose levodopa therapy is not toxic in multiple system atrophy: experimental evidence. Mov Disord 2007a;22(7):969-73. PMID 17427936
220: Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 2008;210(2):421-7. PMID 18222424
221: Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, Wenning GK. Microglial activation mediates neurodegeneration related to oligodendroglial alpha synucleinopathy: implications for multiple system atrophy. Mov Disord 2007b;22(15):2196-203. PMID 17853477
222: Suzuki M, Saigusa H, Shibasaki K, Kodera K. Multiple system atrophy manifesting as complex sleep-disordered breathing. Auris Nasus Larynx 2010;37(1):110-3. PMID 19398176
223: Tada M, Kakita A, Toyoshima Y, et al. Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. Brain 2009;132(Pt 7):1810-9. PMID 19429902
224: Tada M, Onodera O, Tada M, et al. Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy. Arch Neurol 2007;64:256-60. PMID 17296842
225: Tan EK, Skipper L, Chua, et al. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease. Mov Disord 2006;21:997-1001. PMID 16602113
226: Tanaka H, Nishio H, Sasanabe R, Shiomi T. [A case of multiple systemic atrophy (MSA) analyzed by acoustic sound for nocturnal inspiratory stridor.] Nihon Kokyuki Gakkai Zasshi 2007;45(8):604-8. PMID 17763688
227: Tanji K, Mori F, Kakita A, et al. Immunohistochemical localization of NUB1, a synphilin-1-binding protein, in neurodegenerative disorders. Acta Neuropathol 2007;114(4):365-71. PMID 17549501
228: Tanudjojo B, Shaikh SS, Fenyi A, et al. Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons. Nat Commun 2021;12(1):3817. PMID 34155194
229: Taoka T, Kin T, Nakagawa H, et al. Diffusivity and diffusion anisotropy of cerebellar peduncles in cases of spinocerebellar degenerative disease. Neuroimage 2007;37(2):387-93. PMID 17583535
230: Terni B, Rey MJ, Boluda S, et al. Mutant ubiquitin and p62 immunoreactivity in cases of combined multiple system atrophy and Alzheimer's disease. Acta Neuropathol 2007;113(4):403-16. PMID 17237936
231: Tha KK, Terae S, Yabe I, et al. Microstructural white matter abnormalities of multiple system atrophy: in vivo topographic illustration by using diffusion-tensor MR imaging. Radiology 2010;255(2):563-9. PMID 20413765
232: Tison F, Wenning GK, Volonte MA, Poewe WR, Henry P, Quinn NP. Pain in multiple system atrophy. J Neurol 1996;243:153-6. PMID 8750553
233: Todisco M, Alfonsi E, Isaias IU, et al. Vocal cord electromyographic correlates of stridor in multiple system atrophy phenotypes. Parkinsonism Relat Disord 2020;70:31-5. PMID 31809947
234: Trojanowski JQ, Revesz T; Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 2007;33(6):615-20. PMID 17990994
235: Ubhi K, Rockenstein E, Mante M, et al. Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy. Neuroreport 2010;21(6):457-62. PMID 20224454
236: Vanacore N, Bonifati V, Fabbrini G, et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 2000;54(1):114-9. PMID 10636135
237: Vanacore N, Bonifati V, Fabbrini G, et al. Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci 2001;22:97-9. PMID 11487219
238: Vanacore N, Bonifati V, Fabbrini G, et al. Case-control study of multiple system atrophy. Mov Disord 2005;20:158-63. PMID 15382209
239: van der Eecken H, Adams RD, van Bogaert L. Striopallidal-nigral degeneration. A hitherto undescribed lesion in paralysis agitans. J Neuropathol Exp Neurol 1960;19:159-61.
240: van de Warrenburg BP, Cordivari C, Ryan AM, et al. The phenomenon of disproportionate antecollis in Parkinson's disease and multiple system atrophy. Mov Disord 2007;22(16):2325-31. PMID 17960814
241: Van Laere K, Clerinx K, D'Hondt E, de Groot T, Vandenberghe W. Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease. J Nucl Med 2010;51(4):588-95. PMID 20237023
242: Vetrugno R, D'Angelo R, Cortelli P, Plazzi G, Vignatelli L, Montagna P. Impaired cortical and autonomic arousal during sleep in multiple system atrophy. Clin Neurophysiol 2007a;118(11):2512-8. PMID 17897876
243: Vetrugno R, Liguori R, Cortelli P, et al. Sleep-related stridor due to dystonic vocal cord motion and neurogenic tachypnea/tachycardia in multiple system atrophy. Mov Disord 2007b;22(5):673-8. PMID 17266093
244: von Lewinski F, Werner C, Jorn T, Mohr A, Sixel-Doring F, Trenkwalder C. T2()-weighted MRI in diagnosis of multiple system atrophy: a practical approach for clinicians. J Neurol 2007;254(9):1184-8. PMID 17361340
245: Walter U, Dressler D, Probst T, et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol 2007;64(11):1635-40. PMID 17998447
246: Wang H, An R, Chen Y, et al. Clinical features of multiple system atrophy with or without rapid eye movement behavior disorder: a cross-sectional study in southwest China. Clin Auton Res 2020;30(3):239-45. PMID 31832904
247: Waragai M, Yamada T, Matsuda H. Evaluation of brain perfusion SPECT using an easy Z-score imaging system (eZIS) as an adjunct to early-diagnosis of neurodegenerative diseases. J Neurol Sci 2007;260(1-2):57-64. PMID 17493637
248: Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002;125(Pt 5):1070-83. PMID 11960896
249: Wen XD, Li HF, Wang HX, Ni W, Dong Y, Wu ZY. Mutation analysis of COQ2 in Chinese patients with cerebellar subtype of multiple system atrophy. CNS Neurosci Ther 2015;21(8):626-30. PMID 26096180
250: Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994;117:835-45. PMID 7922469
251: Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013;12(3):264-74. PMID 23391524
252: Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord 2005;20 Suppl 12:S67-76. PMID 16092094
253: Wenning GK, Kraft E, Beck R, et al. Cerebellar presentation of multiple system atrophy. Mov Disord 1997;12:115-7. PMID 8990065
254: Wenning GK, Krismer F, Poewe W. New insights into atypical parkinsonism. Curr Opin Neurol 2011;24(4):331-8. PMID 21577106
255: Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord 2022;37(6):1131-48. PMID 35445419
256: Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004;19:1391-402. PMID 15452868
257: Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P). Mov Disord 2010;25(3):357-62. PMID 20108379
258: Winge K, Jennum P, Lokkegaard A, Werdelin L. Anal sphincter EMG in the diagnosis of parkinsonian syndromes. Acta Neurol Scand 2010;121(3):198-203. PMID 19785640
259: Winkler AS, Marsden J, Parton M, Watkins PJ, Chaudhuri KR. Erythropoietin deficiency and anaemia in multiple system atrophy. Mov Disord 2001;16:233-9. PMID 11295775
260: Woerman AL, Watts JC, Aoyagi A, Giles K, Middleton LT, Prusiner SB. α-synuclein: multiple system atrophy prions. Cold Spring Harb Perspect Med 2018;8(7). PMID 28213437
261: Woitalla D, Braak H, Tredici KD, et al. [Transcraniel ultrasound in the differential diagnosis of Parkinson's disease.] Fortschr Neurol Psychiatr 2010;78 Suppl 1:S25-30. PMID 20195938
262: Wu YT, Shyu KK, Jao CW, et al. Fractal dimension analysis for quantifying cerebellar morphological change of multiple system atrophy of the cerebellar type (MSA-C). Neuroimage 2010;49(1):539-51. PMID 19635573
263: Wu YT, Shyu KK, Jao CW, et al. Quantifying cerebellar atrophy in multiple system atrophy of the cerebellar type (MSA-C) using three-dimensional gyrification index analysis. Neuroimage 2012;61(1):1-9. PMID 22401757
264: Wullner U, Schmitz-Hubsch T, Abele M, Antony G, Bauer P, Eggert K. Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease. J Neural Transm 2007;114(9):1161-5. PMID 17510732
265: Yamanaka Y, Asahina M, Mathias CJ, Akaogi Y, Koyama Y, Hattori T. Skin vasodilator response to local heating in multiple system atrophy. Mov Disord 2007;22(16):2405-8. PMID 17894341
266: Yamashita F, Hirayama M, Nakamura T, et al. Pupillary autonomic dysfunction in multiple system atrophy and Parkinson's disease: an assessment by eye-drop tests. Clin Auton Res 2010;20(3):191-7. PMID 20127386
267: Yokoyama T, Hasegawa K, Horiuchi E, Yagishita S. Multiple system atrophy (MSA) with massive macrophage infiltration in the ponto-cerebellar afferent system. Neuropathology 2007;27(4):375-7. PMID 17899692
268: Yomono HS, Kurisaki H, Hebisawa A, Sakiyama Y, Saito Y, Murayama S. [Autopsy case of SCA2 with Parkinsonian phenotype.] Rinsho Shinkeigaku 2010;50(3):156-62. PMID 20235484
269: Yoshida M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 2007;27(5):484-93. PMID 18018485
270: Xia C, Postuma RB. Diagnosing multiple system atrophy at the prodromal stage. Clin Auton Res 2020;30(3):197-205. PMID 32232688
271: Z'graggen WJ, Hess CW, Humm AM. Acute fluid ingestion in the treatment of orthostatic intolerance - important implications for daily practice. Eur J Neurol 2010;17(11):1370-6. PMID 20412295
272: Zhang L, Haga N, Ogawa S, et al. Case of possible multiple system atrophy with a characteristic imaging finding of open bladder neck during storage phase as an initial sign. Int J Urol 2017;24(11):816-9. PMID 28809053
273: Zhang K, Zeng Y, Song C, Fu Y, Wan Q. The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease. J Neurol 2010;257(9):1486-91. PMID 20405138
274: Zhao T, Severijnen L, van der Weiden M, et al. FBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophy. J Neuropathol Exp Neurol 2013;72(6):482-8. PMID 23656991
275: Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci 2010;289(1-2):74-80. PMID 19740484

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Robert Fekete MD

Dr. Fekete of New York Medical College received consultation fees from Acadia Pharmaceutical, Acorda, Adamas/Supernus Pharmaceuticals, Amneal/Impax, Kyowa Kirin, Lundbeck Inc., Neurocrine Inc., and Teva Pharmaceutical, Inc.
See Profile

Former Authors

Lawrence I Golbe MD

Patient Profile

Age range of presentation: 19 to 65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Other specified degenerative diseases of basal ganglia: G23.8
ICD-11: Multiple system atrophy, Cerebellar type: 8D87.00

Multiple system atrophy, Parkinsonism: 8D87.01

Other specified multiple system atrophy: 8D87.0Y

Multiple system atrophy, unspecified: 8D87.0Z

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Multiple system atrophy

Associated Disorders

Obstructive sleep apnea
Rapid eye movement sleep behavior disorder

Differential Diagnosis

Ataxia with oculomotor apraxia
Cerebrotendinous xanthomatosis
Corticobasal degeneration
Dementia with Lewy bodies
Fragile-X tremor ataxia syndrome
- Fragile-X-associated tremor-ataxia syndrome
- FXTAS
- Gaucher disease
- Hereditary spastic paraplegias
- Late-onset cerebellar ataxia
- Mitochondrial diseases
- Mitochondriopathies
- Multi-infarct states
- Parkinson disease
- Perry syndrome
- POLG1 gene mutations
- Progressive supranuclear palsy
- Pure autonomic failure
- Spinocerebellar ataxias
- Sporadic adult-onset ataxia of unknown etiology

Also Relevant

Ataxia
Basal ganglia: functional anatomy and neuropharmacology
Botulinum toxin treatment of neurologic disorders
Central alveolar hypoventilation
Corticobasal degeneration
- Deep brain stimulation in movement disorders
- Functional movement disorders
- Gait disorders
- Hyposmia in neurodegenerative disorders
- Imaging of movement disorders
- Motor control of movement disorders
- Myoclonus
- Neurogenic bladder
- Neurologic disorders associated with behavioral symptoms
- Neuro-ophthalmology of movement disorders
- Obstructive sleep apnea
- Outpatient rehabilitation of chronic neurologic conditions
- Parasomnias
- Parkinson disease
- Periodic limb movements
- Principles of rehabilitation of patients with neurologic disorders
- Progressive supranuclear palsy
- Pure autonomic failure
- Rapid eye movement sleep behavior disorder
- Rating scales of movement disorders
- Riluzole
- Sleep and cerebral degenerative disorders
- Sleep and parkinsonism
- Sleep-related laryngospasm
- Urinary dysfunction in neurologic disorders
- Vertical gaze palsy

Clinical Categories

Movement Disorders

Patient Handouts

Web References

Guidelines

UMSARS and other MSA rating scales

Multiple system atrophy (MSA) …

Multiple system atrophy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Diagnostic workup

Table 1. Multiple System Atrophy Diagnostic Criteria

Table 2. Additional Diagnostic Criteria for Possible Multiple System Atrophy

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

Multiple system atrophy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Diagnostic workup

Table 1. Multiple System Atrophy Diagnostic Criteria

Table 2. Additional Diagnostic Criteria for Possible Multiple System Atrophy

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

This is an article preview.
Start a Free Account
to access the full version.